Metabotropic glutamate subtype-2 and -3 receptor positive allosteric modulators and uses thereof
Metabotropic glutamate subtype-2 and -3 receptor positive allosteric modulators address the limitations of current treatments by modulating glutamatergic transmission, effectively treating central nervous system disorders, neurodegenerative diseases, and substance abuse, offering improved symptom reduction and treatment efficacy.
Patent Information
- Application Number
- PCT/US2024/034470
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-06-20
- Filing Date
- 2024-06-18
- Publication Date
- 2024-12-26
AI Technical Summary
Current treatments for neuropsychiatric disorders, neurodegenerative diseases, and substance abuse lack effective solutions, particularly for conditions involving aberrant glutamatergic signaling, as existing therapies have limitations in addressing the underlying glutamatergic imbalances and associated symptoms.
Development of metabotropic glutamate subtype-2 and -3 (mGlu2/3) receptor positive allosteric modulators (PAMs) to modulate glutamatergic transmission, which are administered in various forms for intravenous, subcutaneous, oral, inhalation, nasal, dermal, or ophthalmic administration, targeting central nervous system disorders, substance abuse, and addictive behaviors.
The mGlu2/3 receptor PAMs effectively treat central nervous system disorders, neurodegenerative diseases, and substance abuse by modulating glutamatergic signaling, reducing symptoms and improving treatment outcomes with potential for fewer adverse effects compared to existing therapies.
Smart Images

Figure IMGF000003_0001 
Figure IMGF000003_0002 
Figure IMGF000004_0001
Abstract
Description
METABOTROPIC GLUTAMATE SUBTYPE-2 AND -3 RECEPTOR POSITIVE ALLOSTERIC MODULATORS AND USES THEREOFCROSS-REFERENCE
[0001] This application claims the benefit of U.S. Provisional Patent Application No. 63 / 509,142, filed on June 20, 2023, which is incorporated herein by reference in its entirety.STATEMENT AS TO FEDERALLY SPONSORED RESEARCH
[0002] This invention was made with government support under R01 DA023926, U01 DA041731, and U01 DA051077 awarded by the National Institutes of Health. The government has certain rights in the invention.INCORPORATION BY REFERENCE
[0003] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.FIELD OF THE INVENTION
[0004] Described herein are metabotropic glutamate subtype -2 and -3 (mGlu2 / 3) (collectively Group II mGlus) receptor positive allosteric modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders in which metabotropic glutamate receptors are involved.SUMMARY
[0005] Described herein are metabotropic glutamate subtype -2 and -3 (mGlu2 / 3) (collectively Group II mGlus) receptor positive allosteric modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders in which metabotropic glutamate receptors are involved.
[0006] In one aspect, provided herein is a compound of Formula (I):Formula (I), or a pharmaceutically acceptable salt thereof; wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11are each selected from hydrogen or deuterium, provided that at least one of R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11is deuterium; and wherein each of R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11that is deuterium has a deuterium enrichment of at least 90%. In some embodiments, at least one of R10and R11is deuterium. In some embodiments, R10and R11are each deuterium. In some embodiments, at least two of R1, R2, R3, R4, R5, R6, R7, R8, and R9are deuterium. In some embodiments, at least four of R1, R2, R3, R4, R5, R6, R7, R8, and R9are deuterium. In some embodiments, R4, R5, R6, and R7are each deuterium. In some embodiments, R2, R3, R8, and R9are each deuterium. In some embodiments, R1, R2, R3, R8, and R9are each deuterium. In some embodiments, the compound of Formula (I) is selected from:or a pharmaceutically acceptable salt thereof. In some embodiments, each of R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11that is deuterium has a deuterium enrichment of at least about 95%. In some embodiments, each of R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11that is deuterium has a deuterium enrichment of at least 98%. In some embodiments, each of R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11that is deuterium has a deuterium enrichment of no more than 99.9%.
[0007] In another aspect, provided herein is a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt, or solvate thereof, and a pharmaceutically acceptable excipient.
[0008] In another aspect, provided herein is a compound of Formula (II):Formula (II), or a pharmaceutically acceptable salt thereof; wherein ring B is selected from (i) cyclopentyl substituted with one or more -OH, (ii) unsubstituted cyclopentyl, or (iii) cyclopentenyl optionally substituted with one or more -OH; and W is hydrogen or a pyranyl substituted by one or more groups independently selected from - OH and -C(=O)OH. In some embodiments ring B is unsubstituted cyclopentyl. In some embodiments ring B is cyclopentyl substituted with -OH. In some embodiments, ring B is selected from:. In some embodiments ring B is cyclopentenyl optionally substituted with one or more -OH. In some embodiments ring B is selected from:embodiments, the compound of Formula (II), is selected from:
[0009] In another aspect, provided herein is a pharmaceutical composition comprising a compound of Formula (II), or a pharmaceutically acceptable salt, or solvate thereof, and at least one pharmaceutically acceptable excipient.
[0010] In some embodiments, the pharmaceutical composition is formulated for administration to a mammal by intravenous administration, subcutaneous administration, oral administration, inhalation, nasal administration, dermal administration, or ophthalmic administration. In some embodiments, the pharmaceutical composition is in the form of a tablet, a pill, a capsule, a liquid, a suspension, a gel, a dispersion, a solution, an emulsion, an ointment, or a lotion.
[0011] In one aspect, provided herein is a method of treating a central nervous disorder (CNS) disorder in a subject in need thereof, the method comprising a step of administering to the subject in need thereof, a therapeutically effective amount of a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt thereof, thereby treating the disorder. In some embodiments, the CNS disorder is a neurodegenerative disease. In some embodiments,the CNS disorder is schizophrenia. In some embodiments, the neurodegenerative disease is Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, or Lou Gehrig's disease (Amyotrophic Lateral Sclerosis or ALS).
[0012] In one aspect, provided herein is a method of treating substance abuse in a subject in need thereof, the method comprising the step of administering to the subject in need thereof, a therapeutically effective amount of a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt thereof, wherein the therapeutically effective amount is sufficient to diminish, inhibit or eliminate desire for and / or consumption of the substance in the subject. In some embodiments, the substance is nicotine, alcohol, an opioid, an amphetamine, a methamphetamine, or cocaine.
[0013] In one aspect, provided herein is a method for treating an addictive disorder in a subject in need thereof, the method comprising the steps of: a) administering to the subject in need thereof, an effective amount of a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt thereof, during a first time period wherein the subject expects to be in an environment wherein, or exposed to stimuli in the presence of which, the subject habitually uses an addictive substance; and b) administering an effective amount of the compound of any one of Formula (I) or Formula (II), or a pharmaceutically acceptable salt thereof, during a second time period wherein the subject is suffering from withdrawal. In some embodiments, the addictive disorder is nicotine addiction. In some embodiments, the addictive disorder is alcohol addiction. In some embodiments, the addictive disorder is opioid addiction. In some embodiments, the addictive disorder is amphetamine addiction. In some embodiments, the addictive disorder is methamphetamine addiction. In some embodiments, the addictive disorder is cocaine addiction.BACKGROUND
[0014] Glutamate is the major excitatory neurotransmitter in the mammalian central nervous system (CNS), mediating fast synaptic transmission through ion channels, primarily the a- amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMP A) and kainate ionotropic glutamate receptor subtypes. The metabotropic glutamate (mGlu) receptors are a family of eight G protein-coupled receptors that are activated by glutamate and perform a modulatory function in the nervous system. The Group II mGlu receptors include the mGlu2 and mGlu3 receptor subtypes, which couple with Gi / o proteins to negatively regulate the activity of adenylyl cyclase. Localization studies suggest that mGlu2 receptors act predominantly aspresynaptic autoreceptors to modulate the release of glutamate into the synaptic cleft (Cartmell, J. and Schoepp, D. D. J. Neurochem. 2000, 75, 889-907). On the other hand, mGlu3 receptors exhibit a broad distribution in the brain and have been shown to be present on astrocytes (Durand, D. et al. Neuropharmacology 2013, 66, 1-11). In addition, it has been shown that activation of mGlu3 receptors is required for the neuroprotective effects of mGlu2 / 3 agonists toward N-methyl-D-aspartate (NMD A) neurotoxicity in mixed cultures of astrocytes and neurons, whereas activation of mGlu2 receptors may be harmful (Corti, C. et al. J. Neurosci. 2007, 27, 8297-8308).
[0015] Various brain regions, including the cerebral cortex, hippocampus, striatum, amygdala, frontal cortex, and nucleus accumbens, display high levels of mGlu2 and mGlu3 receptor binding. This distribution pattern suggests a role for the mGlu2 / 3 receptor subtypes in the pathology of neuropsychiatric disorders such as anxiety, depression, schizophrenia, drug dependence, neuroprotection, Alzheimer’s disease, and sleep / wake architecture. Thus, there is significant potential for the development of selective Group II mGlu receptor activators, including agonists and positive allosteric modulators (PAMs), for the treatment of CNS diseases caused by aberrant glutamatergic signaling.DETAILED DESCRIPTIONDefinitions
[0016] Unless defined otherwise, all terms of art, notations and other technical and scientific terms or terminology used herein are intended to have the same meaning as is commonly understood by one of ordinary skill in the art to which the claimed subject matter pertains. In some cases, terms with commonly understood meanings are defined herein for clarity and / or for ready reference, and the inclusion of such definitions herein should not necessarily be construed to represent a substantial difference over what is generally understood in the art.
[0017] Throughout this application, various embodiments may be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the disclosure. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4,from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.
[0018] In the following description, certain specific details are set forth in order to provide a thorough understanding of various embodiments. However, one skilled in the art will understand that the invention may be practiced without these details. In other instances, well- known structures have not been shown or described in detail to avoid unnecessarily obscuring descriptions of the embodiments. Unless the context requires otherwise, throughout the specification and claims which follow, the word “comprise” and variations thereof, such as, “comprises” and “comprising” are to be construed in an open, inclusive sense, that is, as “including, but not limited to.” Further, headings provided herein are for convenience only and do not interpret the scope or meaning of the claimed invention.
[0019] As used in this specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the content clearly dictates otherwise. It should also be noted that the term “or” is generally employed in its sense including “and / or” unless the content clearly dictates otherwise.
[0020] The terms below, as used herein, have the following meanings, unless indicated otherwise:
[0021] The term “optional” or “optionally” means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not.
[0022] As used in the specification and claims, the singular forms “a”, “an” and “the” include plural references unless the context clearly dictates otherwise. For example, the term “a sample” includes a plurality of samples, including mixtures thereof.
[0023] The term “assessing” refers to a form of measurement. The term includes determining if an element is present or not (for example, detection). This term can include quantitative, qualitative or quantitative and qualitative determinations. Assessing can be relative or absolute depending on the context.
[0024] The terms “subject,” “individual,” or “patient” are often used interchangeably herein. A “subject” can be a biological entity containing expressed genetic materials. The biological entity can be a plant, animal, or microorganism, including, for example, bacteria, viruses, fungi, and protozoa. The subject can be tissues, cells and their progeny of a biological entity obtained in vivo or cultured in vitro. The subject can be a mammal. The mammal can be a human. The subject may be diagnosed or suspected of being at high risk for a disease. Insome cases, the subject is not necessarily diagnosed or suspected of being at high risk for the disease.
[0025] The term “zzz vivo" is used to describe an event that takes place in a subject’s body.
[0026] The term “ex vivo" is used to describe an event that takes place outside of a subject’s body. An ex vivo assay is not performed on a subject. Rather, it is performed upon a sample separate from a subject. An example of an ex vivo assay performed on a sample is an “zzz vitro" assay.
[0027] The term “zzz vitro" is used to describe an event that takes places contained in a container for holding laboratory reagent such that it is separated from the biological source from which the material is obtained. In vitro assays can encompass cell-based assays in which living or dead cells are employed. In vitro assays can also encompass a cell-free assay in which no intact cells are employed.
[0028] As used herein, the term “about” a number refers to that number plus or minus 10% of that number. The term “about” a range refers to that range minus 10% of its lowest value and plus 10% of its greatest value.
[0029] As used herein, the terms “treatment” or “treating” are used in reference to a pharmaceutical or other intervention regimen for obtaining beneficial or desired results in the recipient. Beneficial or desired results include but are not limited to a therapeutic benefit and / or a prophylactic benefit. A therapeutic benefit may refer to eradication or amelioration of symptoms or of an underlying disorder being treated. Also, a therapeutic benefit can be achieved with the eradication or amelioration of one or more of the physiological symptoms associated with the underlying disorder such that an improvement is observed in the subject, notwithstanding that the subject may still be afflicted with the underlying disorder. A prophylactic effect includes delaying, preventing, or eliminating the appearance of a disease or condition, delaying or eliminating the onset of symptoms of a disease or condition, slowing, halting, or reversing the progression of a disease or condition, or any combination thereof. For prophylactic benefit, a subject at risk of developing a particular disease, or to a subject reporting one or more of the physiological symptoms of a disease may undergo treatment, even though a diagnosis of this disease may not have been made.
[0030] The terms “co-administration” or the like, as used herein, are meant to encompass administration of the selected therapeutic agents to a single patient, and are intended to include treatment regimens in which the agents are administered by the same or different route of administration or at the same or different time.
[0031] The terms “effective amount” or “therapeutically effective amount,” as used herein, refer to a sufficient amount of an agent or a compound being administered which may relieve to some extent one or more of the symptoms of the disease or condition being treated. The result can be reduction and / or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system. For example, an “effective amount” for therapeutic uses is the amount of the composition comprising a compound as disclosed herein required to provide a clinically significant decrease in disease symptoms. An appropriate “effective” amount in any individual case may be determined using techniques, such as a dose escalation study.
[0032] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.Compounds
[0033] In one aspect, provided herein is a compound of Formula (I):Formula (I), or a pharmaceutically acceptable salt thereof; wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11are each selected from hydrogen or deuterium, provided that at least one of R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11is deuterium; and wherein each of R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11that is deuterium has a deuterium enrichment of at least 90%. In some embodiments, at least one of R10and R11is deuterium. In some embodiments, R10is deuterium. In some embodiments, R10has a deuterium enrichment of at least 90 % percent. In some embodiments, R10has a deuterium enrichment of at least 95 % percent. In some embodiments, R10has a deuterium enrichment of at least 98 % percent. In some embodiments, R10has a deuterium enrichment of at least 99 % percent. In some embodiments, R10has a deuterium enrichment of at least 99.5 % percent. In some embodiments, R10has a deuterium enrichment of at least 99.9 % percent. In some embodiments, R10and R11are each deuterium. In some embodiments, R10and R11each have a deuterium enrichment of at least 90 %. In some embodiments, R10and R11each have a deuterium enrichment of at least 95 %. In some embodiments, R10and R11each have a deuterium enrichment of at least 98 %. In some embodiments, R10and R11each have adeuterium enrichment of at least 99 %. In some embodiments, R10and R11each have a deuterium enrichment of at least 99.5 %. In some embodiments, R10and R11each have a deuterium enrichment of at least 99.9 %. In some embodiments, at least two of R1, R2, R3, R4, R5, R6, R7, R8, and R9are deuterium. In some embodiments, at least two of R1, R2, R3, R4, R5, R6, R7, R8, and R9have a deuterium enrichment of at least 80 %. In some embodiments, at least two of R1, R2, R3, R4, R5, R6, R7, R8, and R9have a deuterium enrichment of at least 90 %. In some embodiments, at least two of R1, R2, R3, R4, R5, R6, R7, R8, and R9have a deuterium enrichment of at least 95 %. In some embodiments, at least two of R1, R2, R3, R4, R5, R6, R7, R8, and R9have a deuterium enrichment of at least 98 % enriched with deuterium. In some embodiments, at least two of R1, R2, R3, R4, R5, R6, R7, R8, and R9have a deuterium enrichment of at least 99 %. In some embodiments, at least four of R1, R2, R3, R4, R5, R6, R7, R8, and R9are deuterium. In some embodiments, at least four of R1, R2, R3, R4, R5, R6, R7, R8, and R9have a deuterium enrichment of at least 80 percent. In some embodiments, at least four of R1, R2, R3, R4, R5, R6, R7, R8, and R9have a deuterium enrichment of at least 90 percent. In some embodiments, at least four of R1, R2, R3, R4, R5, R6, R7, R8, and R9have a deuterium enrichment of at least 95 percent. In some embodiments, at least four of R1, R2, R3, R4, R5, R6, R7, R8, and R9have a deuterium enrichment of at least 98 percent. In some embodiments, at least four of R1, R2, R3, R4, R5, R6, R7, R8, and R9have a deuterium enrichment of at least 99 percent. In some embodiments, R4, R5, R6, and R7are each deuterium. In some embodiments, R4, R5, R6, and R7each have a deuterium enrichment of at least 80 percent. In some embodiments, R4, R5, R6, and R7each have a deuterium enrichment of at least 90 percent. In some embodiments, R4, R5, R6, and R7each have a deuterium enrichment of at least 95 percent. In some embodiments, R4, R5, R6, and R7each have a deuterium enrichment of at least 98 percent. In some embodiments, R4, R5, R6, and R7each have a deuterium enrichment of at least 99 percent. In some embodiments, R2, R3, R8, and R9are each deuterium. In some embodiments, R2, R3, R8, and R9each have a deuterium enrichment of at least 80 percent. In some embodiments, R2, R3, R8, and R9each have a deuterium enrichment of at least 90 percent. In some embodiments, R2, R3, R8, and R9each have a deuterium enrichment of at least 95 percent. In some embodiments, R2, R3, R8, and R9each have a deuterium enrichment of at least 98 percent. In some embodiments, R2, R3, R8, and R9each have a deuterium enrichment of at least 99 percent. In some embodiments, R1, R2, R3, R8, and R9are each deuterium. In some embodiments, R1, R2, R3, R8, and R9each have a deuterium enrichment of at least 80 percent. In some embodiments, R1, R2, R3, R8, and R9each have a deuterium enrichment of at least 90 percent. In some embodiments, R1, R2,R3, R8, and R9each have a deuterium enrichment of at least 95 percent. In some embodiments, R1, R2, R3, R8, and R9each have a deuterium enrichment of at least 98 percent. In some embodiments, R1, R2, R3, R8, and R9each have a deuterium enrichment of at least 99 percent. In some embodiments, the compound of Formula (I) is selected from:embodiments, each of R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11that is deuterium has a deuterium enrichment of at least about 95%. In some embodiments, each of R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11that is deuterium has a deuterium enrichment of at least 98%. In some embodiments, each of R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11that is deuterium has a deuterium enrichment of no more than 99.9%.
[0034] In another aspect, provided herein is a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
[0035] In another aspect, provided herein is a compound of Formula (II):Formula (II), or a pharmaceutically acceptable salt thereof; wherein ring B is selected from (i) cyclopentyl substituted with one or more -OH, (ii) unsubstituted cyclopentyl, or (iii) cyclopentenyl optionally substituted with one or more -OH; and W is hydrogen or a pyranyl substituted by one or more groups independently selected from - OH and -C(=O)OH. In some embodiments ring B is unsubstituted cyclopentyl. In someembodiments ring B is cyclopentyl substituted with -OH. In some embodiments, ring B isIn some embodiments ringIn some embodiments ringsome embodiments ring B isIn some embodiments ring B is. In some embodiments ring B is cyclopentyl substituted with more than one -OH In some embodiments ring B is cyclopentenyl optionally substituted with one or more -OH. In some embodiments ring B is selected from:In some embodiments ringIn some embodiments ring B is. In some embodiments ring B isIn some embodiments ring B isIn some embodiments W is selected from: hydrogenembodiments W is selected from:some embodiments, W is hydrogen.In some embodiments, W is a pyranyl group substituted by one or more groups independently selected from -OH and -C(=O)OH. In some embodiments, W is a glucuronide or glucuronoside. In some embodiments, the compound of Formula (II), is selected from:
[0036] In one aspect, provided herein is a pharmaceutical composition comprising a compound of Formula (II), or a pharmaceutically acceptable salt, or solvate thereof, and atleast one pharmaceutically acceptable excipient. In some embodiments, the pharmaceutical composition is formulated for administration to a mammal by intravenous administration, subcutaneous administration, oral administration, inhalation, nasal administration, dermal administration, or ophthalmic administration. In some embodiments, the pharmaceutical composition is formulated for administration to a mammal by intravenous administration. In some embodiments, the pharmaceutical composition is formulated for administration to a mammal by subcutaneous administration. In some embodiments, the pharmaceutical composition is formulated for administration to a mammal by oral administration. In some embodiments, the pharmaceutical composition is formulated for administration to a mammal by inhalation administration. In some embodiments, the pharmaceutical composition is formulated for administration to a mammal by nasal administration. In some embodiments, the pharmaceutical composition is formulated for administration to a mammal by dermal administration. In some embodiments, the pharmaceutical composition is formulated for administration to a mammal by ophthalmic administration.
[0037] In some embodiments, the pharmaceutical composition is in the form of a tablet, a pill, a capsule, a liquid, a suspension, a gel, a dispersion, a solution, an emulsion, an ointment, or a lotion. In some embodiments, the pharmaceutical composition is in the form of a tablet. In some embodiments, the pharmaceutical composition is in the form of a pill. In some embodiments, the pharmaceutical composition is in the form of a capsule. In some embodiments, the pharmaceutical composition is in the form of a liquid. In some embodiments, the pharmaceutical composition is in the form of a suspension. In some embodiments, the pharmaceutical composition is in the form of a gel. In some embodiments, the pharmaceutical composition is in the form of a solution. In some embodiments, the pharmaceutical composition is in the form of a solvate. In some embodiments, the pharmaceutical composition is in the form of a dispersion. In some embodiments, the pharmaceutical composition is in the form of an ointment. In some embodiments, the pharmaceutical composition is in the form of an emulsion. In some embodiments, the pharmaceutical composition is in the form of a lotion.
[0038] In some embodiments, the compound is any one of the compounds represented in Table 1, or a pharmaceutically acceptable salt or solvate thereof.Table 1
[0039] In some embodiments, provided herein is a pharmaceutical composition comprising a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, or solvate thereof, and at least one pharmaceutically acceptable excipient. In some embodiments, the pharmaceutical composition is formulated for administration to a mammal by intravenous administration, subcutaneous administration, oral administration, inhalation, nasal administration, dermal administration, or ophthalmic administration. In some embodiments, the pharmaceutical composition is formulated for administration to a mammal by intravenous administration. In some embodiments, the pharmaceutical composition is formulated for administration to a mammal by subcutaneous administration. In some embodiments, the pharmaceutical composition is formulated for administration to a mammal by oral administration. In some embodiments, the pharmaceutical composition is formulated for administration to a mammal by inhalation administration. In some embodiments, the pharmaceutical composition is formulated for administration to a mammal by nasal administration. In some embodiments, the pharmaceutical composition is formulated for administration to a mammal by dermal administration. In some embodiments, thepharmaceutical composition is formulated for administration to a mammal by ophthalmic administration. In some embodiments, the pharmaceutical composition is in the form of a tablet, a pill, a capsule, a liquid, a suspension, a gel, a dispersion, a solution, an emulsion, an ointment, or a lotion. In some embodiments, the pharmaceutical composition is in the form of a tablet. In some embodiments, the pharmaceutical composition is in the form of a pill. In some embodiments, the pharmaceutical composition is in the form of a capsule. In some embodiments, the pharmaceutical composition is in the form of a liquid. In some embodiments, the pharmaceutical composition is in the form of a suspension. In some embodiments, the pharmaceutical composition is in the form of a gel. In some embodiments, the pharmaceutical composition is in the form of a dispersion. In some embodiments, the pharmaceutical composition is in the form of a solution. In some embodiments, the pharmaceutical composition is in the form of a solvate. In some embodiments, the pharmaceutical composition is in the form of an emulsion. In some embodiments, the pharmaceutical composition is in the form of an ointment. In some embodiments, the pharmaceutical composition is in the form of a lotion.Methods of treatment
[0040] In one aspect, provided herein is a method of treating a central nervous disorder (CNS) disorder in a subject in need thereof, the method comprising a step of administering to the subject in need thereof, a therapeutically effective amount of a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt thereof, thereby treating the disorder. In some embodiments, the method of treating a central nervous disorder (CNS) disorder in a subject in need thereof comprises a step of administering to the subject in need thereof, a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, thereby treating the disorder. In some embodiments, the method of treating a central nervous disorder (CNS) disorder in a subject in need thereof comprises a step of administering to the subject in need thereof, a therapeutically effective amount of a compound of Formula (II), or a pharmaceutically acceptable salt thereof, thereby treating the disorder. In some embodiments, the method of treating a central nervous disorder (CNS) disorder in a subject in need thereof comprises a step of administering to the subject in need thereof, a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, thereby treating the disorder. In some embodiments, the method of treating a central nervous disorder (CNS) disorder in a subject in need thereof comprises a step of administering to the subject in need thereof, a therapeutically effectiveamount of a compound of Formula (II), or a pharmaceutically acceptable salt thereof, thereby treating the disorder. In some embodiments, the compound of Formula (I) is selected from:embodiments, the compound of Formula (II), is selected from:pharmaceutically acceptable salt thereof. In some embodiments, the CNS disorder is an addictive disorder. In some embodiments, the addictive disorder is nicotine addiction, alcohol addiction, opioid addiction, amphetamine addiction, methamphetamine addiction, or cocaine addiction. In some embodiments, the addictive disorder is nicotine addiction. In some embodiments, the addictive disorder is alcohol addiction. In some embodiments, the addictive disorder is opioid addiction. In some embodiments, the addictive disorder is opioid addiction. In some embodiments, the addictive disorder is amphetamine addiction. In some embodiments, the addictive disorder is methamphetamine addiction. In some embodiments, the addictive disorder is cocaine addiction. In some embodiments, the CNS disorder is schizophrenia. In some embodiments, the CNS disorder is a neurodegenerative disease. In some embodiments, the neurodegenerative disease is Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, or Lou Gehrig's disease (Amyotrophic Lateral Sclerosis or ALS). In some embodiments, the neurodegenerative disease progresses gradually. In some embodiments, the neurodegenerative disease progresses over at least one year. In some embodiments, the neurodegenerative disease progresses rapidly. In some embodiments, the neurodegenerative disease progresses in less than one year. In some embodiments, the neurodegenerative disease is hereditary. In some embodiments, the neurodegenerative disease is of environmental origin such as heavy metal exposure.
[0041] In one aspect, provided herein is a method of treating substance abuse in a subject in need thereof, the method comprising the step of administering to the subject in need thereof, a therapeutically effective amount of a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt thereof, wherein the therapeutically effective amount is sufficient to diminish, inhibit or eliminate desire for and / or consumption of the substance in the subject.
[0042] In one aspect, provided herein is a method of treating substance abuse in a subject in need thereof, the method comprising the step of administering to the subject in need thereof, a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the therapeutically effective amount is sufficient to diminish, inhibit or eliminate desire for and / or consumption of the substance in the subject. In one aspect, provided herein is a method of treating substance abuse in a subject in need thereof,the method comprising the step of administering to the subject in need thereof, a therapeutically effective amount of a compound of Formula (II), or a pharmaceutically acceptable salt thereof, wherein the therapeutically effective amount is sufficient to diminish, inhibit or eliminate desire for and / or consumption of the substance in the subject. In some embodiments, the compound of Formula (I) is selected from:embodiments, the compound of Formula (II), is selected from:, or a pharmaceutically acceptable salt thereof. In some embodiments, the substance is nicotine, alcohol, opioids, amphetamines, methamphetamines, or cocaine. In some embodiments, the substance is nicotine. In some embodiments, the substance is alcohol. In some embodiments, the substance is an opioid. In some embodiments, the substance is one or more opioids. In some embodiments, the substance is an amphetamine. In some embodiments, the substance is one or more amphetamines. In some embodiments, the substance is a methamphetamine. In some embodiments, the substance is one or more methamphetamines. In some embodiments, the substance is cocaine.
[0043] In one aspect, provided herein is a method for treating an addictive disorder in a subject in need thereof, the method comprising the steps of: a) administering to the subject in need thereof, an effective amount of a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt thereof, during a first time period, wherein the subject expects to be in an environment wherein, or exposed to stimuli in the presence of which, the subject habitually uses an addictive substance; and b) administering an effective amount of the compound of any one of Formula (I) or Formula (II), or a pharmaceutically acceptable salt thereof, during a second time period wherein the subject is suffering from withdrawal. In some embodiments, the method comprises administering to the subject in need thereof, an effective amount of a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt thereof, during a first time period, wherein the subject expects to be in an environment wherein, or exposed to stimuli in the presence of which, the subject habitually uses an addictive substance. In some embodiments, the method comprises administering an effective amount of the compound of any one of Formula (I) or Formula (II), or a pharmaceutically acceptable salt thereof, during a second time period wherein the subject is suffering from withdrawal. In some embodiments, the compound of Formula (I) is selected from:, or a pharmaceutically acceptable salt thereof. In some embodiments, the compound of Formula (II), is selected from:
[0044] Provided herein is also a method for treating an addictive disorder in a subject in need thereof, the method comprising the steps of: a) administering to the subject an effective amount of the compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt thereof, during a first time period wherein the subject expects to be in an environment in which the subject habitually uses an addictive substance, or exposed to stimuli which results in the subject habitually using an addictive substance; and b) administering to the subject an effective amount of the compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt thereof, during a second time period wherein the subject is suffering from withdrawal. In some embodiments, the addictive disorder is nicotine addiction, alcoholaddiction, opioid addiction, amphetamine addiction, methamphetamine addiction, or cocaine addiction. In some embodiments, the addictive disorder is nicotine addiction. In some embodiments, the addictive disorder is alcohol addiction. In some embodiments, the addictive disorder is opioid addiction. In some embodiments, the addictive disorder is amphetamine addiction. In some embodiments, the addictive disorder is methamphetamine addiction. In some embodiments, the addictive disorder is cocaine addiction.Further Forms of Compounds Disclosed HereinIsomer s / Stereoisomers
[0045] In some embodiments, the compounds described herein exist as geometric isomers. In some embodiments, the compounds described herein possess one or more double bonds. The compounds presented herein include all cis, trans, syn, anti, entgegen (E), and zusammen (Z) isomers as well as the corresponding mixtures thereof. In some situations, the compounds described herein possess one or more chiral centers and each center exists in the R configuration, or S configuration. The compounds described herein include all diastereomeric, enantiomeric, and epimeric forms as well as the corresponding mixtures thereof. In additional embodiments of the compounds and methods provided herein, mixtures of enantiomers and / or diastereoisomers, resulting from a single preparative step, combination, or interconversion are useful for the applications described herein. In some embodiments, the compounds described herein are prepared as their individual stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereoisomeric compounds, separating the diastereomers and recovering the optically pure enantiomers. In some embodiments, dissociable complexes are preferred. In some embodiments, the diastereomers have distinct physical properties (e.g., melting points, boiling points, solubilities, reactivity, etc.) and are separated by taking advantage of these dissimilarities. In some embodiments, the diastereomers are separated by chiral chromatography, or preferably, by separation / resolution techniques based upon differences in solubility. In some embodiments, the optically pure enantiomer is then recovered, along with the resolving agent, by any practical means that would not result in racemization.Labeled compounds
[0046] In some embodiments, the compounds described herein exist in their isotopically- labeled forms. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such isotopically-labeled compounds. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such isotopically-labeled compounds as pharmaceutical compositions. Thus, insome embodiments, the compounds disclosed herein include isotopically-labeled compounds, which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds disclosed herein include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine, and chloride, such as2H (D),3H,13C,14C,15N,18O,170,31P,32P,35S,18F, and36C1, respectively. Compounds described herein, and the pharmaceutically acceptable salts or solvates thereof which contain the aforementioned isotopes and / or other isotopes of other atoms are within the scope of this invention.
[0047] Disclosed herein are compounds with a greater ratio of deuterium to hydrogen than what occurs naturally. In some cases, the natural ratio of about 1 deuterium atom for every 6,600 proton atoms, or about 0.015%, may be enriched to a substantially different ratio. Deuterium enrichment factor refers to the increase in ratio of deuterium atoms to hydrogen atoms within a given molecular substituent or position. In some embodiments, one or more molecular substituents comprising hydrogen atoms are replaced with one or more molecular substituents comprising deuterium atoms. In some embodiments, a position designated as having deuterium has a minimum deuterium enrichment factor of at least 3500 (52.5% deuterium incorporation), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium incorporation), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation) at each designated deuterium position. Deuterium enrichment and deuterium enrichment factor may be confirmed through experimental techniques including nuclear magnetic resonance and mass spectroscopy. With regard to the compounds provided herein, when a particular atomic position is designated as having deuterium or “D” or “d”, it is understood that the position is enriched with deuterium atoms at that position and is substantially greater than the naturally occurring percentage of deuterium atoms to hydrogen atoms.Pharmaceutically acceptable salts
[0048] In some embodiments, the compounds described herein exist as their pharmaceutically acceptable salts. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such pharmaceutically acceptable salts. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such pharmaceutically acceptable salts as pharmaceutical compositions.
[0049] In some embodiments, the compounds described herein possess acidic or basic groups and therefore react with any of a number of inorganic or organic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt. In some embodiments, these salts are prepared in situ during the final isolation and purification of the compounds disclosed herein, or a solvate thereof, or by separately reacting a purified compound in its free form with a suitable acid or base, and isolating the salt thus formed.
[0050] Examples of pharmaceutically acceptable salts include those salts prepared by reaction of the compounds described herein with a mineral, organic acid or inorganic base, such salts including, acetate, bromide, chloride, formate, iodide, phosphate, and sulfonate.
[0051] Further, the compounds described herein can be prepared as pharmaceutically acceptable salts formed by reacting the free base form of the compound with a pharmaceutically acceptable inorganic or organic acid, including, but not limited to, inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid metaphosphoric acid, and the like; and organic acids such as acetic acid, propionic acid, hexanoic acid, trifluoroacetic acid, and muconic acid.
[0052] In some embodiments, those compounds described herein which comprise a free acid group react with a suitable base, such as the hydroxide, carbonate, bicarbonate, or sulfate, of a pharmaceutically acceptable metal cation, with ammonia, or with a pharmaceutically acceptable organic primary, secondary, tertiary, or quaternary amine. Representative salts include the alkali or alkaline earth salts, such as lithium, sodium, potassium, calcium, and magnesium, and aluminum salts. Illustrative examples of bases include sodium hydroxide, potassium hydroxide, and sodium carbonate.
[0053] Representative organic amines useful for the formation of base addition salts include diisopropylethylamine, piperazine and the like.Solvates
[0054] In some embodiments, the compounds described herein exist as solvates. The invention provides for methods of treating diseases by administering such solvates. The invention further provides for methods of treating diseases by administering such solvates as pharmaceutical compositions.
[0055] Solvates contain either stoichiometric or non-stoichiometric amounts of a solvent, and, in some embodiments, are formed during the process of crystallization with pharmaceutically acceptable solvents such as water, ethanol, and the like. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol. Solvates of the compounds described herein can be conveniently prepared or formed duringthe processes described herein. By way of example only, hydrates of the compounds described herein can be conveniently prepared by recrystallization from an aqueous / organic solvent mixture, using organic solvents including, but not limited to, dioxane, tetrahydrofuran or methanol. In addition, the compounds provided herein can exist in unsolvated as well as solvated forms. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of the compounds and methods provided herein.Tautomers
[0056] In some situations, compounds exist as tautomers. The compounds described herein include all possible tautomers within the formulas described herein. Tautomers are compounds that are interconvertible by migration of a hydrogen atom, accompanied by a switch of a single bond and adjacent double bond. In bonding arrangements where tautomerization is possible, a chemical equilibrium of the tautomers may exist. All tautomeric forms of the compounds disclosed herein are contemplated. The exact ratio of the tautomers depends on several factors, including temperature, solvent, and pH.Certain definitionsAddiction and addictive disorders
[0057] Addiction refers to the repeated desire to consume a substance, composition, or mixture. In some cases, addiction is towards a substance of abuse. Often, addiction yields adverse effects upon cessation of consuming a substance, composition, or mixture towards which there is an addiction. Withdrawal refers to physiological and psychological effects due to ceasing consumption of an addictive substance or substance of abuse. Withdrawal and its unpleasant effects often complicate the cessation of consuming addictive substances that are toxic or dangerous.Addictive Substances
[0058] Addiction may emerge with respect to a variety of chemical substances and mixtures. In some cases, addiction is towards a narcotic. Some examples of substances of addiction are nicotine, alcohol, opioids, amphetamines, methamphetamines, or cocaine. In some cases, the addiction is towards a certain class of substances such as narcotics, benzodiazepines, serotonin reuptake inhibitors, or norepinephrine reuptake inhibitors. Addictive substances may predominately be a single molecular entity, or a mixture of one or more addictive substances and fillers or excipients. In some embodiments, an addictive substance is a single compound in a particular form such as a salt, a suspension, or a dry powder. In some embodiments, an addictive substance is one or more compounds. Further physiological and technical aspects of addiction, addictive disorders, withdrawal, and addictive substances maybe found in The Diagnostic and Statistical Manual of Mental Disorders (5th ed.; DSM-5; American Psychiatric Association, 2013).Anxiety
[0059] Anxiety is an unpleasant state of inner turmoil, often accompanied by nervous behavior, such as pacing back and forth, somatic complaints and rumination. It is the subjectively unpleasant feelings of dread over anticipated events, such as the feeling of imminent death. Anxiety is a feeling of fear, worry, and uneasiness, usually generalized and unfocused as an overreaction to a situation that is only subjectively seen as menacing. It is often accompanied by muscular tension, restlessness, fatigue and problems in concentration. Anxiety can be appropriate, but when experienced regularly the individual may suffer from an anxiety disorder.
[0060] In some embodiments, the compounds described herein are mGlu2 / 3 receptor PAM used for treating anxiety symptoms. The method includes administering to a subject in need thereof, an effective amount of at least one mGlu2 / 3 receptor PAM, thereby treating the anxiety symptoms.Depression
[0061] Depression is a state of low mood and aversion to activity that can affect a person's thoughts, behavior, feelings and sense of well-being. People with depressed mood can feel sad, anxious, empty, hopeless, helpless, worthless, guilty, irritable or restless. They may lose interest in activities that were once pleasurable, experience loss of appetite or overeating, have problems concentrating, remembering details or making decisions, and may contemplate, attempt or commit suicide. Insomnia, excessive sleeping, fatigue, aches, pains, digestive problems or reduced energy may also be present. Depressed mood is a feature of some psychiatric syndromes such as major depressive disorder, but it may also be a normal reaction to life events such as bereavement, a symptom of some bodily ailments or a side effect of some drugs and medical treatments.
[0062] Blockade of mGlu2 / 3 receptors has antidepressant properties as reflected in reversal of the negative affective (depression-like) aspects of nicotine withdrawal. Thus, blockade of mGlu2 and mGlu3 reverses depression-like symptoms observed during drug withdrawal, and possibly depression observed during drug dependence (Ahmed, S. H., et al. Nature Neuroscience, 5: 625-626 (2002)). Therefore, administration of an effective amount of an antagonist of mGlu2 and mGlu3 is likely to be efficacious for treating non-drug-induced depressions, based on the known neurobiological similarities mediating drug- and non-drug- induced depressions (Markou et al. 1998; Barr et al., 2002; Cryan et al., 2002; Harrison et al.,Neuropsychopharmacology, 25:55-71 (2001); Markou A and Kenny P J 2002, Neurotoxicity Research, 4(4), 297-313).
[0063] In some embodiments, the compounds described herein are mGlu2 / 3 receptor PAM used for treating depressive symptoms and anxiety symptoms of depression. The method includes administering to a subject in need thereof, an effective amount of at least one antagonist which modulates the mGlu2 and / or mGlu3 receptor, thereby treating the depressive symptoms and anxiety symptoms. In another aspect, the disclosure provides at least one mGlu2 / 3 receptor PAM that can be administered during a depressed time period, wherein the subject experiences symptoms of depression.Nicotine Addiction
[0064] Nicotine dependence is an addiction to tobacco products caused by the drug nicotine. Nicotine dependence means a person can't stop using the substance, even though it's causing harm. Nicotine produces physical and mood-altering effects in your brain that are temporarily pleasing. These effects make you want to use tobacco and lead to dependence. At the same time, stopping tobacco use causes withdrawal symptoms, including irritability and anxiety.
[0065] In certain aspects, the effective amount of at least one mGlu2 / 3 receptor PAM is administered to decrease nicotine consumption. For example, in one aspect an effective amount of a PAM of mGlu2 and / or mGlu3, can be administered to decrease nicotine consumption. In certain aspects of the disclosure, a PAM of mGlu2 and / or mGlu3 is administered while a subject is experiencing withdrawal. In another aspect of the disclosure, a PAM of mGlu2 and / or mGlu3 is administered during a time period when a subject is actively using an addictive substance. In another aspect of the disclosure, a PAM of mGlu2 and / or mGlu3 is administered during a time period when a subject is actively experiencing depression associated with drug use or not associated with drug use.Cocaine Addiction
[0066] Cocaine addiction remains a major public health problem in the United States. There are several sources of motivation that contribute to the continuance of cocaine abuse, including: the positive reinforcing effects of cocaine; and the alleviation of the negative affective aspects of cocaine withdrawal. Conditioned stimuli previously associated with cocaine administration may also elicit conditioned "cravings" leading to the reinstatement of cocaine-seeking behavior even after a prolonged period of abstinence. Recent studies indicate that the neuronal mechanisms underlying various aspects of drug abuse may differ necessitating the use of different treatments for specific aspects of drug dependence. To date, a safe and effective pharmacological treatment for cocaine dependence has yet to beidentified. Thus, there remains a need for the design of new chemical entities that can be used as novel medications for cocaine addiction.
[0067] It has been found that repeated cocaine exposure may alter the function of Group II metabotropic glutamate receptors (mGluII receptors), pointing to a possible role of these mGlu subtypes in the development of cocaine dependence. The mGluII receptor positive modulators may decrease the reinforcing effects of self-administered cocaine in rats that had extended access to cocaine, a putative model of cocaine dependence while having no effect in rats with limited access to cocaine. Positive mGluII receptor modulators may attenuate discriminatory cue-induced reinstatement of cocaine self-administration. In contrast, mGluII receptor negative modulators may reverse the reward deficits associated with early cocaine abstinence.
[0068] Cocaine addiction is a chronic relapsing disorder and remains a major public health problem in the United States. The number of cases of cocaine abuse has steadily risen in the past decade. To date, a safe and effective pharmacological treatment for cocaine dependence has yet to be identified, which highlights the need to design new chemical entities that may become future novel medications for cocaine addiction. Recent evidence suggests that mGlus play a significant role in the abuse-related effects of cocaine. For example, repeated administration of cocaine has been shown to alter the function of mGlus, as well as their regulation by cysteine / glutamate exchange in the nucleus accumbens. These findings suggest that mGlu2 may be involved in the development of cocaine dependence and may represent a possible target for drug discovery against different aspects of cocaine abuse and dependence. There are several sources of motivation that contribute to the maintenance of cocaine abuse. These include the positive reinforcing effects of cocaine and alleviation of the negative affective aspects of cocaine withdrawal. Further, conditioned stimuli previously associated with cocaine administration may elicit conditioned "cravings" leading to the reinstatement of cocaine-seeking behavior even after a prolonged period of abstinence. Recent studies suggest that the neuronal mechanisms underlying drug self-administration are different from those mediating relapse vulnerability during abstinence, and different from those mediating the negative effects of early drug withdrawal. Therefore, it is important to explore concurrently the neurochemical mechanisms that contribute to the different aspects of cocaine dependence using animal models assessing the positive reinforcing effects of cocaine, the negative affective symptoms of early withdrawal, and cue-induced reinstatement of cocaine-seeking behavior after prolonged abstinence from drug intake. The discovery and preclinical testing of highly selective mGluII receptor modulators with good brain penetration may significantlycontribute to the discovery of novel therapeutic treatments for different aspects cocaine dependence.
[0069] The intravenous drug self-admini strati on procedure provides a reliable and robust model of human drug consumption. This procedure in animals provides a valid model of human drug abuse as studied in a controlled laboratory situation. Self-administration of drugs of abuse is thought to provide an operational measure of the rewarding effects of the drug. Increases in excitatory glutamatergic transmission are likely to contribute to the positive reinforcing properties of addictive drugs. Neurochemical studies indicate that systemic cocaine administration increase glutamate levels in the ventral tegmental area (VTA) and the nucleus accumbens, brain structures that are integral components of the extended amygdala, a brain circuit mediating the reward effects of all major drugs of abuse. The administration of a positive modulator of mGluII receptors may decrease cocaine self-administration in rats with extended access to cocaine by decreasing glutamate neurotransmission in limbic structures similar to the effects of mGlu2 / 3 agonists. In contrast, a negative modulator of mGluII receptors may most likely have no effect on cocaine self-administration, or possibly may shift the dose-response curve to the left, potentiating the reinforcing effects of cocaine.
[0070] Another challenge for the treatment of drug addiction is chronic vulnerability to relapse. One of the factors that precipitates drug craving and relapse to drug taking behavior in humans is environmental stimuli previously associated with drug-taking. These drug- associated stimuli can be divided into two categories: discrete drug cues (e.g., drug paraphernalia) that are associated with the rewarding effects of the drug, and discriminatory and contextual drug cues (e.g., specific environmental stimuli or specific environments) that predicts drug availability. In animals, discrete, discriminative and contextual conditioned cues can reinstate drug-seeking behavior, measured by variables derived from the reinstatement procedure. Recent data showed that reinstatement of cocaine-seeking was attenuated by systemic injections of N-acetylcysteine that leads to a tonic increase in nucleus accumbens glutamate levels in rats. Preliminary results in humans suggest that N- acetyl cysteine attenuated cocaine craving in addicted humans. Further, exposure to environmental cues previously paired with cocaine injections increased glutamate in the nucleus accumbens. A potential use for mGlu2 / 3 agonists as pharmacotherapeutic agents to inhibit relapse was recently shown using different rodent models of reinstatement. In some embodiments, mGlu2 / 3 agonists attenuate cocaine-seeking behavior induced by discriminative cocaine-associated cues or by cocaine priming. In addition, mGlu2 / 3 agonists have been shown to inhibit cue-induced reinstatement of heroin-seeking, alcohol-seeking,nicotine-seeking, and also inhibited food-seeking behavior. The decreases in cue-induced food responding suggest that the administration of mGlu2 / 3 agonist decreased motivation for a natural reinforcer also. Further, it has been hypothesized that susceptibility to relapse due to cue reactivity increases gradually over periods of weeks or months. Thus, the administration of a positive modulator of mGluII receptors during prolonged abstinence from cocaine selfadministration may decrease, while a negative modulator of mGluII receptors may have no effect on cocaine-seeking behavior induced by discriminative stimuli associated with cocaine availability.
[0071] Avoidance and alleviation of the negative affective state of early drug withdrawal with further drug abuse is hypothesized to be an important source of motivation that contributes significantly to the development of compulsive drug use and relapse during early abstinence. It has been hypothesized that susceptibility to relapse due to affective withdrawal symptoms peaks within days of cessation reflecting early rise in withdrawal symptoms. Thus, pharmacological treatments that reverse the depression-like aspects of early cocaine withdrawal would remove an important source of motivation that contributes to relapse to drug abuse shortly after the initial cessation of drug administration. Abrupt abstinence following chronic exposure to drugs of abuse, including cocaine results in a negative affective state reflected in significant elevations in intracranial self-stimulation (ICSS) thresholds. ICSS thresholds are thought to provide an operational measure of brain reward function; thus elevations in ICSS thresholds reflect deficits in brain reward function. This threshold elevation is opposite to the lowering of ICSS thresholds observed after cocaine administration that reflects an increase in brain reward function that most likely underlies, or at least relates to, cocaine's euphorigenic effects. This increase in brain reward function associated with cocaine consumption is considered essential for the establishment and maintenance of cocaine self-administration behavior. The mechanisms that contribute to withdrawal-induced reward deficits or reward facilitation remain unclear. Group II mGlus have been implicated in the synaptic adaptations that occur in response to chronic drug exposure and contribute to the aversive behavioral withdrawal syndrome. The role of glutamate transmission in the early phase of cocaine withdrawal has not been studied extensively. However, based on the nicotine dependence findings and the hypothesis of overlapping mechanisms of withdrawal from different drugs of abuse, one may hypothesize that decreased glutamatergic neurotransmission may also partly mediate cocaine withdrawal in cocaine-dependent subjects.
[0072] In some embodiments, the compounds described herein are mGlu2 / 3 receptor PAM used for treating cocaine addiction.Schizophrenia
[0073] Schizophrenia is a devastating psychiatric illness that afflicts approximately 1% of the worldwide population. The core symptoms observed in schizophrenic patients include positive symptoms (thought disorder, delusions, hallucinations, paranoia), negative symptoms (social withdrawal, anhedonia, apathy, paucity of speech) and cognitive impairments such as deficits in perception, attention, learning, short- and long-term memory and executive function. The cognitive deficits in schizophrenia are one of the major disabilities associated with the illness and are considered a reliable predictor of long-term disability and treatment outcome. Currently available antipsychotics effectively treat the positive symptoms, but provide modest effects on the negative symptoms and cognitive impairments. Furthermore, some patients are unresponsive to current antipsychotic treatments and several of these agents are associated with adverse side effects, including disturbances in motor function, weight gain, and sexual dysfunction. Thus, there is a need for new treatment strategies for schizophrenia that provide major improvements in efficacy across multiple symptom clusters and have fewer adverse effects.
[0074] Although the underlying pathophysiology of schizophrenia remains unknown, accumulating evidence points to disruptions in multiple neurotransmitter systems that modulate neural circuits important for normal affect, sensory processing, and cognition. In particular, early clinical findings demonstrated that changes in glutamatergic transmission produced by antagonists of the N-methyl-D-aspartate (NMD A) subtype of ionotropic glutamate receptors, including phencyclidine (PCP), result in a state of psychosis in humans that is similar to that observed in schizophrenic patients. These studies suggest that agents that increase NMDA receptor function have potential as therapeutics for the treatment of all major symptom clusters (positive, negative, cognitive) of the disease. More recently, studies indicate that reduced NMDA receptor function induces complex changes in transmission through cortical and subcortical circuits that involve both glutamatergic and GABAergic synapses and include downstream increases in transmission at glutamatergic synapses in the prefrontal cortex. Importantly, these circuit changes might share common features with changes in brain circuit activities that occur in schizophrenia patients. One hypothesis is that NMDA receptors involved in these symptoms might reside at glutamatergic synapses on GABAergic projection neurons in midbrain regions as well as GABAergic interneurons and glutamatergic projection neurons in key cortical and limbic regions For example, undernormal conditions the activation of NMD A receptors localized on GABAergic projection neurons in subcortical regions, such as the nucleus accumbens, provides inhibitory control on excitatory glutamatergic thalamocortical neurons that project to pyramidal neurons in the prefrontal cortex (PFC). Hypofunction or blockade of these NMDA receptors on midbrain inhibitory GABAergic neurons could result in a disinhibition of glutamatergic thalamocortical inputs to pyramidal neurons in the PFC. This disinhibition would lead to a subsequent increased activity of glutamatergic thalamic neurons and increased activity mediated by the DL-a-amino-3-hydroxy-5-methylisoxasole-4-propionate (AMP A) subtype of glutamate receptors at thalamocortical synapses in the PFC. Based on this model, manipulations that enhance NMDA receptor function, such as activation of metabotropic glutamate receptor subtype 5 (mGlu5) located on GABAergic neurons, have potential as a novel approach to the treatment of schizophrenia. An alternative approach might be to reduce excitatory glutamatergic transmission at key synapses, such as thalamocortical synapses in the PFC, by activation of metabotropic glutamate receptor subtypes 2 and 3 (mGlu2 and mGlu3) presynaptically located in these synapses. Although other viable models of circuit changes associated with schizophrenia exist, this hypothesis provides one possible framework within which to consider effects of ligands at mGlu receptors that might be relevant to schizophrenia.
[0075] A large number of preclinical and clinical studies provide strong evidence that agonists of mGlu2 and mGlu3 (group II mGlu receptors) also have potential as a novel approach to the treatment of schizophrenia. Consistent with the animal studies, clinical studies reveal that a highly selective agonist of group II mGlu receptors has robust efficacy in improving ratings for positive and negative symptoms in patients with schizophrenia. Unlike currently marketed antipsychotic agents, there were no major adverse events reported for the mGlu2 / 3 agonist in the clinical studies to date. However, further clinical studies may be required to fully establish safety of these compounds after long-term dosing in schizophrenic patients, as well as assess possible efficacy on the cognitive impairments in these patients. Taken together, these findings represent an important breakthrough and could ultimately lead to introduction of group II mGlu receptor activators as a fundamentally novel approach to the treatment of schizophrenia. As mentioned above, animal studies reveal that the psychotomimetic agents increase activity of glutamatergic synapses in the PFC, and hyperactivity of glutamate neurotransmission in the PFC and limbic structures has been postulated to play a critical role in the pathophysiology of schizophrenia. Interestingly, effects of psychotomimetic agents on glutamatergic transmission in the PFC are blocked bygroup II mGlu receptor agonists. Although it is not yet clear whether this action of group II mGlu receptor agonists is mechanistically related to the antipsychotic actions of these compounds, these actions fit well with current models of disruptions in subcortical and cortical circuits that might be involved in the psychotomimetic effects of NMD A receptor antagonists and the range of symptoms observed in schizophrenia patients. Despite advances in development of group II mGlu receptor agonists, it is not yet clear whether orthosteric agonists of these receptors may reach the market for broad clinical use. Long-term administration of group II mGlu receptor agonists induces robust tolerance in at least one rodent model that has been used to predict antipsychotic efficacy. These orthosteric agonists also activate both mGlu2 and mGlu3 and do not provide insights into which of these group II mGlu receptor subtypes is most important for clinical efficacy. Although, recent findings demonstrate that the antipsychotic-like effects of mGlu2 / 3 receptor agonists are absent in mGlu2-knockout, but not mGlu3 -knockout, mice. Thus, it is possible that positive allosteric modulators of mGlu2 might be an alternative approach that could provide greater selectivity and other potential advantages to orthosteric agonists.
[0076] In some embodiments, group II mGlu receptor agonists are useful in the treatment of schizophrenia. In some embodiments, selective mGlu2 PAMs represent a novel approach to the treatment of these disorders that is devoid of the adverse effects associated with currently available drugs.
[0077] In some embodiments, the compounds described herein are mGlu2 / 3 receptor PAM used for treating schizophrenia. The method includes administering to a subject in need thereof, an effective amount of at least one mGlu2 / 3 receptor PAM, thereby treating schizophrenia.Alzheimer ’s Disease
[0078] Alzheimer's disease (AD), also known as Alzheimer disease, or just Alzheimer's, accounts for 60% to 70% of cases of dementia. It is a chronic neurodegenerative disease that usually starts slowly and gets worse over time. The most common early symptom is difficulty in remembering recent events (short term memory loss). As the disease advances, symptoms can include: problems with language, disorientation (including easily getting lost), mood swings, loss of motivation, not managing self-care, and behavioral issues. As a person's condition declines, she or he often withdraws from family and society. Gradually, bodily functions are lost, ultimately leading to death. Although the speed of progression can vary, the average life expectancy following diagnosis is three to nine years.
[0079] Various brain regions, including the cerebral cortex, hippocampus, striatum, amygdala, frontal cortex and nucleus accumbens, display high levels of mGlu2 and mGlu3 receptor binding. This distribution pattern suggests a role for the mGlu2 / 3 receptor subtypes in the pathology of neuropsychiatric disorders such as Alzheimer’s disease.
[0080] In some embodiments, the compounds described herein are mGlu2 / 3 receptor PAM used for treating Alzheimer’s disease. The method includes administering to a subject in need thereof, an effective amount of at least one mGlu2 / 3 receptor PAM, thereby treating Alzheimer’s disease.Huntington ’s Disease
[0081] Huntington's disease (HD) is a neurodegenerative genetic disorder that affects muscle coordination and leads to mental decline and behavioral symptoms. Symptoms of the disease can vary between individuals and affected members of the same family, but usually progress predictably. The earliest symptoms are often subtle problems with mood or cognition. A general lack of coordination and an unsteady gait often follows. As the disease advances, uncoordinated, jerky body movements become more apparent, along with a decline in mental abilities and behavioral symptoms. Physical abilities gradually worsen until coordinated movement becomes difficult. Mental abilities generally decline into dementia. Complications such as pneumonia, heart disease, and physical injury from falls reduce life expectancy to around twenty years from the point at which symptoms begin. Physical symptoms can begin at any age from infancy to old age, but usually begin between 35 and 44 years of age.
[0082] Excitotoxic injury to striatum by dysfunctional cortical input or aberrant glutamate uptake may contribute to Huntington's disease (HD) pathogenesis. Daily subcutaneous injection with a maximum tolerated dose (MTD) of the mGlu2 / 3 agonist LY379268 (20mg / kg) beginning at 4 weeks has been found to dramatically improves the phenotype in R6 / 2 mice (the most commonly used animal model of Huntington’s disease) (Reiner et al. Brain Research 1473 (2012) 161-172). For example, normalization of motor function in distance traveled, speed, the infrequency of pauses, and the ability to locomote in a straight line, and a rescue of a 15-20% striatal neuron loss at 10 weeks were observed.
[0083] In some embodiments, the compounds described herein are mGlu2 / 3 receptor PAM used for treating Huntington’s disease. The method includes administering to a subject in need thereof, an effective amount of at least one mGlu2 / 3 receptor PAM, thereby treating Huntington’s disease.Amyotrophic Lateral Sclerosis
[0084] Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s Disease, is a debilitating disorder characterized by rapidly progressive motor neuron degeneration, which results into weakness, muscle atrophy and spasticity. Riluzole is the only drug that improves survival of ALS patients, only to a modest extent. Thus, there is an urgent need for treatments that slow the progression of ALS. Familial ALS (FALS) is caused by mutations of several genes including SOD1 (type-1 superoxide dismutase). Although SOD1 mutations account for only 20% of FALS and about 2% of sporadic ALS, SOD1 mutant mice recapitulate several features of human ALS, and are widely employed as model for ALS. The validity of this model is strengthened by the evidence that SOD1 aggregates are detected in the spinal cord of people with sporadic ALS or with ALS caused by mutations of genes other than SOD1. The mechanisms by which SOD1 misfolding damages motor neurons are only partially elucidated and involve glutamate excitotoxicity, mitochondrial dysfunction, disruption of axonal transport, and abnormalities in astrocytes and microglia. One of the potential mechanisms of excitotoxicity in ALS is a reduced expression of the glutamate transporter, GLT-1, which clears glutamate from the synapses.
[0085] Enhancement of glial-derived neurotrophic factor (GDNF) is an established therapeutic target for amyotrophic lateral sclerosis (ALS). Activation of group II metabotropic glutamate (mGlu) receptors with the orthosteric agonist, LY379268, enhanced GDNF levels in cultured spinal cord astrocytes from wild-type mice and mGlu2 knockout mice, but not in astrocytes from mGlu3 knockout mice. LY379268 protected Stemberger monoclonal incorporated antibody-32 (SMI-32)+ motor neurons against excitotoxic death in mixed cultures of spinal cord cells, and its action was abrogated by anti -GDNF antibodies. Acute systemic injection of LY379268 (0.5, 1 or 5 mg / kg, i.p.) enhanced spinal cord GDNF levels in wild-type and mGlu2 knockout mice, but not in mGlu3 knockout mice. No tolerance developed to the GDNF-enhancing effect of LY379268 when the drug was continuously delivered for 28 days by means of s.c. osmotic minipumps (0.5-5 mg / day). Continuous infusion of LY379268 also enhanced the expression of the glutamate transporter GLT-1, in the spinal cord. Continuous treatment with 1 or 5 mg / kg / day with LY379268 had a beneficial effect on neurological disability in SOD1G93A mice. At day 40 of treatment, LY379268 enhanced spinal cord levels of GDNF and GLT-1, and rescued spinal cordmotor neurons, as assessed by stereologic counting of SML32+ cells.
[0086] In some embodiments, the compounds described herein are mGlu2 / 3 receptor PAM used for treating ALS. The method includes administering to a subject in need thereof, an effective amount of at least one mGlu2 / 3 receptor PAM, thereby treating ALS.Parkinson ’s Disease
[0087] Parkinson’s disease (PD) is a chronic movement disorder resulting from a disturbance in the normal functioning of the basal ganglia, a collection of subcortical nuclei that are essential for the initiation and control of motor activity. The underlying pathology of the disease is a progressive degeneration of the dopaminergic nigrostriatal tract that manifests as a range of motor deficits including akinesia or bradykinesia, tremor, rigidity and postural instability. Current therapies for PD are essentially based on dopamine replacement and include levodapa (L-DOPA), a precursor of dopamine, and dopamine receptor agonists.These agents are effective in treating the symptoms of the disease in the early stages, but are less effective as the disease progresses when debilitating side-effects such as “on-off ’ fluctuations in efficacy and uncontrollable dyskinesias (involuntary muscle movements) ensue. More importantly, dopaminergic treatments do not halt the disease progression. For these reasons, several investigators have started to focus on nondopaminergic interventions as symptomatic and neuroprotecive strategies in PD.
[0088] Studies have shown that Group II mGlu receptors play some role in alleviating akinesia in the rat. In functional studies (Murray et al. Pharmacology, Biochemistry and Behavior 73 (2002) 455-466), intracerebroventricular administration of LY379268 (1, 5, 10, 20 nmol / 2 > 1) produced a dose-dependent increase in locomotor activity in the reserpine (5 mg / kg ip)-treated rat. In contrast, systemic administration of LY379268 (0.1, 1, 10 mg / kg ip) did not reverse reserpine-induced akinesia and failed to effect rotational behaviour 1 month after unilateral lesioning of the nigrostriatal tract by 6-hydroxydopamine (6-OHDA; 4 mg infused into the substantia nigra (SN)). These results suggest that mGlus may offer a nondopaminergic approach to the treatment of PD.
[0089] In some embodiments, the compounds described herein are mGlu2 / 3 receptor PAM used for treating Parkinson’s disease. The method includes administering to a subject in need thereof, an effective amount of at least one mGlu2 / 3 receptor PAM, thereby treating Parkinson’s disease.Neuroprotection
[0090] In neuroprotective studies (Murray et al. Pharmacology, Biochemistry and Behavior 73 (2002) 455-466), animals were treated with LY379268 (10 mg / kg / day ip) either for 7 days following 6-OHDA injection into the SN (4 mg) or for 21 days following 6-OHDA injectioninto the striatum (10 mg) before measurement of tyrosine hydroxylase immunoreactivity in the striatum and / or SN as an index of neuroprotection. LY379268 provided some protection against nigral infusion of 6-OHDA and also some functional improvement and correction of dopamine turnover was observed. The compound also provided significant protection in the striatum and some protection in the SN against striatal infusion of 6-OHDA.
[0091] Low doses of the mGlu2 / 3 metabotropic glutamate receptor agonist, LY379268 (0.25- 3 mg / kg, i.p.) increased glial cell line-derived neurotrophic factor (GDNF) mRNA and protein levels in the mouse brain, as assessed by in situ hybridization, real-time PCR, immunoblotting, and immunohistochemistry. This increase was prominent in the striatum, but was also observed in the cerebral cortex. GDNF mRNA levels peaked at 3 h and declined afterwards, whereas GDNF protein levels progressively increased from 24 to 72 h following LY379268 injection. The action of LY379268 was lost in mGlu3 receptor knockout mice, but not in mGlu2 receptor knockout mice. In pure cultures of striatal neurons, the increase in GDNF induced by LY379268 required the activation of the mitogen-activated protein kinase and phosphatidylinositol-3-kinase pathways, as shown by the use of specific inhibitors of the two pathways. Both in vivo and in vitro studies led to the conclusion that neurons were the only source of GDNF in response to mGlu3 receptor activation. Remarkably, acute or repeated injections of LY379268 at doses that enhanced striatal GDNF levels (0.25 or 3 mg / kg, i.p.) were highly protective against nigro-striatal damage induced by 1- methyl-4- phenyl-l,2,3,6-tetrahydropyridine in mice, as assessed by stereological counting of tyrosine hydroxylase-positive neurons in the pars compacta of the substantia nigra. It is speculated that selective mGlu3 receptor agonists or enhancers are potential candidates as neuroprotective agents in Parkinson’s disease, and their use might circumvent the limitations associated with the administration of exogenous GDNF. Hence, selective mGlu3 receptor agonists or positive allosteric modulators (PAMs) would potentially be helpful in the treatment of chronic neurodegenerative disorder by providing neuroprotection. Further physiological and technical aspects of mental, neurodegenerative, and other psychological disorders may be found in The Diagnostic and Statistical Manual of Mental Disorders (5th ed.; DSM-5; American Psychiatric Association, 2013).Combination Treatments
[0092] In certain instances, it is appropriate to administer at least one compound of Formula (I) or Formula (II) in combination with another therapeutic agent.
[0093] In one specific embodiment, a compound of Formula (I) or Formula (II) is coadministered with a second therapeutic agent, wherein the compound of Formula (I) orFormula (II) and the second therapeutic agent modulate different aspects of the disease, disorder or condition being treated, thereby providing a greater overall benefit than administration of either therapeutic agent alone.
[0094] For combination therapies described herein, dosages of the co-administered compounds vary depending on the type of co-drug(s) employed, on the specific drug(s) employed, on the disease or condition being treated and so forth. In additional embodiments, when co-administered with one or more other therapeutic agents, the compound provided herein is administered either simultaneously with the one or more other therapeutic agents, or sequentially.
[0095] If administration is simultaneous, the multiple therapeutic agents are, by way of example only, provided in a single, unified form, or in multiple forms.
[0096] In some embodiments, compounds of Formula (I) or Formula (II) are administered to a mammal in combination with one or more additional neurodegenerative disease or disorder therapeutic agent. In some embodiments, the neurodegenerative disease or disorder is Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, or Lou Gehrig's Disease (Amyotrophic Lateral Sclerosis or ALS). In some embodiments, compounds of Formula (I) or Formula (II) are administered to a mammal in combination with one or more additional therapeutic agent that alleviate the symptoms or side effects of a neurodegenerative disease or disorder. In some embodiments the symptoms or side effects a neurodegenerative disease or disorder are dementia, memory loss, dyskinesias, cognitive impairment, tremors, rigidity, slowness of movement, postural instability, involuntary jerking or writhing movements (chorea), slow or abnormal eye movements, difficulty with the physical production of speech or swallowing, psychiatric disorders, muscle cramps and spasms, spasticity, constipation, fatigue, excessive salivation, excessive phlegm, pain, depression, sleep problems, uncontrolled outbursts of laughing or crying.
[0097] In some embodiments, the additional therapeutic agent is an Alzheimer’s disease therapeutic agent. In some embodiments, the additional therapeutic agent is a cholinesterase inhibitor. In some embodiments, the cholinesterase inhibitor is donepezil, galantamine, or rivastigmine. In some embodiments, the additional therapeutic agent is memantine. In some embodiments, the additional therapeutic agent is latrepirdine, idalopridine, or cerlapirdine.
[0098] In some embodiments, the additional therapeutic agent is a Parkinson’s disease therapeutic agent. In some embodiments, the additional therapeutic agent is levodopa. In some embodiments, the additional therapeutic agent is carbidopa-levodopa. In some embodiments, the additional therapeutic agent is a Dopamine agonist. In some embodiments,the dopamine agonist is ropinirole, pramipexole, or rotigotine. In some embodiments, the additional therapeutic agent is a MAO-B inhibitor. In some embodiments, the MAO-B inhibitor is selegiline or rasagiline. In some embodiments, the additional therapeutic agent is a catechol O-methyltransferase (COMT) inhibitor. In some embodiments, the COMT inhibitor is entacapone or tolcapone. In some embodiments, the additional therapeutic agent is an Anticholinergic. In some embodiments, the anticholinergic is benztropine or trihexyphenidyl. In some embodiments, the additional therapeutic agent is amantadine.
[0099] In some embodiments, compounds of Formula (I) or Formula (II) are administered to a mammal in combination with deep brain stimulation.
[0100] In some embodiments, the additional therapeutic agent is a Huntington’s disease therapeutic agent. In some embodiments, the additional therapeutic agent is tetrabenazine. In some embodiments, the additional therapeutic agent is an antipsychotic drug. In some embodiments, the antipsychotic drug is haloperidol, chlorpromazine, risperidone, olanzapine or quetiapine. In some embodiments, the additional therapeutic agent is amantadine, levetiracetam, or clonazepam. In some embodiments, the additional therapeutic agent is an antidepressant. In some embodiments, the antidepressant is citalopram, fluoxetine, or sertraline. In some embodiments, the additional therapeutic agent is a mood-stabilizing drug. In some embodiments, the mood-stabilizing drug is valproate, carbamazepine, or lamotrigine.
[0101] In some embodiments, compounds of Formula (I) or Formula (II) are administered to a mammal in combination with psychotherapy, speech therapy, physical therapy or occupational therapy.
[0102] In some embodiments, the additional therapeutic agent is a Lou Gehrig's Disease (Amyotrophic Lateral Sclerosis or ALS) therapeutic agent. In some embodiments, the additional therapeutic agent is riluzole. In some embodiments, the additional therapeutic agent is baclofen, diazepam, trihexyphenidyl or amitriptyline.
[0103] In some embodiments, compounds of Formula (I) or Formula (II) are administered to a mammal in combination with one or more additional neuropsychiatric disease or disorder therapeutic agent. In some embodiments, a compound of Formula (I) is administered to a mammal in combination with one or more additional neuropsychiatric disease or disorder therapeutic agent. In some embodiments, a compound of Formula (II) is administered to a mammal in combination with one or more additional neuropsychiatric disease or disorder therapeutic agent. In some embodiments, the neuropsychiatric disease or disorder is schizophrenia, anxiety, a sleep disorder, eating disorder, psychosis, or addiction. In some embodiments, the neuropsychiatric disease or disorder is schizophrenia. In someembodiments, the neuropsychiatric disease or disorder is anxiety. In some embodiments, the neuropsychiatric disease or disorder is sleep disorder. In some embodiments, the neuropsychiatric disease or disorder is an eating disorder. In some embodiments, the neuropsychiatric disease or disorder is psychosis. In some embodiments, the neuropsychiatric disease or disorder is schizophrenia. In some embodiments, the neuropsychiatric disease or disorder is an addictive disorder. In some embodiments, the neuropsychiatric disease or disorder is addiction.
[0104] In some embodiments, compounds of Formula (I) or Formula (II) are administered in combination with one or more additional anti-addiction therapeutic agent. In some embodiments, compounds of Formula (I) or Formula (II) are administered in combination with one or more additional anti-addiction therapeutic agent for the treatment of a substance use and / or substance abuse disorder. In some embodiments, the substance use disorder is a nicotine use disorder, a stimulant use disorder, an alcohol use disorder, or an opioid use disorder. In some embodiments, the substance use disorder is a nicotine use disorder. In some embodiments, the substance use disorder is a stimulant use disorder. In some embodiments, the substance use disorder is an alcohol use disorder. In some embodiments, the substance use disorder is an opioid use disorder. In some embodiments, the anti-addiction therapeutic agent is selected from the group consisting of buprenorphine, methadone, naltrexone, subozone, naloxone, acamprosate, disulfiram, bupropion, varenicline, and a nicotine replacement therapy (NRT).
[0105] In some embodiments, the additional therapeutic agent is an antipsychotic. In some embodiments, the antipsychotic is aripiprazole, asenapine, clozapine, iloperidone, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone, chlorpromazine, fluphenazine, haloperidol, or perphenazine. In some embodiments, the additional therapeutic agent is an antidepressant. In some embodiments, the antidepressant is a selective serotonin reuptake inhibitor (SSRI) or a serotonin norepinephrine reuptake inhibitor (SNRI). In some embodiments, the antidepressant is escitalopram, duloxetine, venlafaxine, or paroxetine. In some embodiments, the additional therapeutic agent is an anti-anxiety medication. In some embodiments, the anti-anxiety medication is buspirone. In some embodiments, the additional therapeutic agent is a benzodiazepine. In some embodiments the benzodiazepine is alprazolam, chlordiazepoxide, diazepam, or lorazepam.
[0106] In some embodiments, the additional therapeutic agent is a medication used to treat dependence. In some embodiments, the medication used to treat dependence isbuprenorphine, methadone, naltrexone, subozone, naloxone, acamprosate, disulfiram, bupropion, varenicline, or a nicotine replacement therapy (NRT).Synthesis of compounds
[0107] In some embodiments, the synthesis of compounds described herein are accomplished using means described in the chemical literature, using the methods described herein, or by a combination thereof. In addition, solvents, temperatures, and other reaction conditions presented herein may vary.
[0108] In other embodiments, the starting materials and reagents used for the synthesis of the compounds described herein are synthesized or are obtained from commercial sources, such as, but not limited to, Sigma-Aldrich, Fisher Scientific (Fisher Chemicals), and Acros Organics.
[0109] In further embodiments, the compounds described herein, and other related compounds having different substituents are synthesized using techniques and materials described herein as well as those that are recognized in the field, such as described, for example, in Fieser and Fieser’s Reagents for Organic Synthesis, Volumes 1-17 (John Wiley and Sons, 1991); Rodd’s Chemistry of Carbon Compounds, Volumes 1-5 and Suppiementals (Elsevier Science Publishers, 1989); Organic Reactions, Volumes 1-40 (John Wiley and Sons, 1991), Larock’s Comprehensive Organic Transformations (VCH Publishers Inc., 1989), March, Advanced Organic Chemistry 4th Ed., (Wiley 1992); Carey and Sundberg, Advanced Organic Chemistry 4th Ed., Vols. A and B (Plenum 2000, 2001), and Green and Wuts, Protective Groups in Organic Synthesis 3rd Ed., (Wiley 1999) (all of which are incorporated by reference for such disclosure). General methods for the preparation of compounds as disclosed herein may be derived from reactions and the reactions may be modified by the use of appropriate reagents and conditions, for the introduction of the various moieties found in the formulae as provided herein. In the reactions described, it may be necessary to protect reactive functional groups, for example hydroxy, amino, imino, thio, or carboxy groups, where these are desired in the final product, in order to avoid their unwanted participation in reactions. A detailed description of techniques applicable to the creation of protecting groups and their removal are described in Greene and Wuts, Protective Groups in Organic Synthesis, 3rd Ed., John Wiley & Sons, New York, NY, 1999, and Kocienski, Protective Groups, Thieme Verlag, New York, NY, 1994, which are incorporated herein by reference for such disclosure).Examples
[0110] The following examples are included for illustrative purposes only and are not intended to limit the scope of the invention.I. Chemical Synthesis[OHl] All reactions were performed in oven-dried glassware under an atmosphere of argon with magnetic stirring. All solvents and chemicals used were purchased from Sigma-Aldrich or Acros, and were used as received without further purification. Purity of compounds was established by liquid chromatography -mass spectroscopy (HPLC-MS) and was >95% for all tested compounds. Silica gel column chromatography was carried out using prepacked silica cartridges from RediSep (ISCO Ltd.) and eluted using an Isco Companion system.1H- and13C-NMR spectra were obtained on a Jeol 400 spectrometer at 400 MHz and 100 MHz, respectively. Chemical shifts are reported in 3 (ppm) relative to residual solvent peaks or TMS as internal standards. Coupling constants are reported in Hz. High-resolution ESI-TOF mass spectra were acquired from the Mass Spectrometry Core at The Sanford-Burnham Medical Research Institute (Orlando, Florida). HPLC-MS analyses were performed on a Shimadzu 2010EV LCMS using the following conditions: Kromisil Cl 8 column (reverse phase, 4.6 mm x 50 mm); a linear gradient from 10% acetonitrile and 90% water to 95% acetonitrile and 5% water over 4.5 min; flow rate of 1 mL / min; UV photodiode array detection from 200 to 300 nm.General ProceduresGeneral Procedure 1
[0112] Boronic acid (A) (1.5 mmol), aryl bromide (B) (1.0 mmol), Pd(dppf)C12 (0.073 g, 0.1 mmol) and 2M Na2COs (2 mL) were taken in DME (10 mL), the resulting mixture was heated at reflux for 2 h under an atmosphere of nitrogen, after completion of the reaction, the reaction mixture was cooled to rt, diluted with water and acidified using dil. HC1 and extracted using ethyl acetate (EtOAc) (3 x 25 mL). The combined organic layer was washed with water, brine and dried over anhyd. ISfeSCU. Removal of the solvent followed by reverse phase HPLC yielded the title compound (C).General Procedure 2
[0113] To a solution of 5-hydroxyisoindolin-l-one (B) (1 mmol) CH3CN (ACN) (30 mL) was added K2CO3 (2 mmol), and benzyl bromide (A) (0.6 mmol) the mixture was heated at reflux for 1-2 h. The reaction mixture was filtered, and the solvent was evaporated under reduced pressure to obtain ester (C).General Procedure 3
[0114] The ester (A) (0.15 mmol) was dissolved in 1,2-di chloroethane (1,2-DCE) and after addition of trimethyltinhydroxide (1.5 mmol), the mixture was heated at 60-80 °C until LC- MS analysis indicated a complete reaction. Subsequently, the mixture was concentrated in vacuo, and the residue was taken up in EtOAc (3 x 15 mL). The organic layer was washed with aqueous KHSO4 (0.0 IN) or HC1 (5 %) (3 x 15 mL). The organic layer was then washed with brine (15 mL) and dried over sodium sulfate. Removal of the solvent followed by reverse phase HPLC yielded the desired carboxylic acid (B).General Procedure 4
[0115] Ester (A) (0.4 mmol) was dissolved in tetrahydrofuran (10 mL), 2M Li OH (2 mmol) was added and the mixture was heated at reflux for 30 min. The solvent was evaporated and the residue was dissolved in water and acidified using 2M HC1. The aqueous layer was extracted with EtOAc (3 x 10 mL) and the combined organic layer was washed with water, brine and dried over anhydrous Na2SO4. The solvent was evaporated in vacuo to obtain thecrude acid (B) as a yellow solid. The crude residue was purified by reverse phase column chromatography (Acetonitrile; H2O solvent system) to give the desired carboxylic acid (B).General Procedure 5
[0116] To a solution of ester (A) (1.86 mmol) in dioxane / LLO (5: 1, 20 mL), 2M LiOH (4.7 mL) was added. The mixture was stirred at 60 °C for 4 h. The reaction was cooled to rt, diluted with water and acidified with IN HC1 to pH 2 and extracted with EtOAc (3 x 25 mL). The solvent was removed the residue was purified with Cl 8 reverse phase column to afford the desired carboxylic acid (B).General Procedure 6
[0117] At room temperature, to a cyclopentanone (A) (2.84 mmol) DCM solution (15 mL) was added Ti(OiPr)4 (0.806 g, 2.84 mmol), followed by the addition of benzylamine (B) (2.84 mmol). The reaction mixture was stirred for 1 hour and the solvent was removed. The residue was dissolved into methanol (25 mL) and cooled to 0 °C. Then NaBD4 (8.01 mmol) or NaBFL was slowly added to this solution and the reaction mixture was warmed up to room temperature and stirred for 2 hours. Then the solvent was removed and the residue was purified by flash silica gel chromatography (DCM / EtOAc) to give the desired amine product N-benzylcyclopentanamine. The N-benzylcyclopentanamine was dissolved in methanol (10 mL) and hydrogenated (1 atm of H2) in presence of Pd / C at rt for 12 h. Reaction mixture was passed through a short pad of celite and washed with methanol 3 times. Removal of the methanol gave the desired primary amine (C).General Procedure 7
[0118] To a stirred solution of benzyl bromide (B) (0.77 mmol) in ACN (5 mL) was added amine (A) (0.77 mmol) followed by potassium carbonate (0.21 g, 1.5 mmol). The resulting mixture was heated at 80 °C for 12 h. Cooled to rt, excess solvent was removed under vacuum and diluted with water and EtOAc. Organic layer collected, and aqueous layer was extracted three times with EtOAc (3 x 10 mL). Combined organic layer was washed with water, brine and dried over anhyd. sodium sulfate. Removal of the solvent followed by column chromatography yielded the desired methoxy precursor of the desired product (C).
[0119] The above methoxy precursor was taken in dry DCM (50 mL) and cooled in an ice bath, under N2 atmosphere. To the cooled mixture, IM BB solution (1.54 mL) in DCM (5 mL) was added dropwise and the resulting mixture was gradually warmed to rt and stirred at that temp for 12 h. Reaction mixture was carefully quenched by the addition of water and stirred at room temperature for 1 h. After that the solvent was removed under reduced pressure and the crude material thus obtained was re-dissolved in minimum amount of MeOH (1 mL), and excess water was added and vigorously stirred. The precipitate thus formed was collected by filtration, washed with water and dried under vacuum to yield the phenol (C).General Procedure 8
[0120] NaBD4(3 mmol) or NaBH4(3 mmol) was added to a solution of benzaldehyde (A) (2 mmol) in MeOH (5 mL) at 0 °C. The resulting reaction mixture was stirred at 0 °C for 1 h. The reaction mixture was quenched by the addition of water and the solvent was evaporated under reduced pressure. The water layer was extracted with EtOAc (3 x 30 mL). The organic layers were combined, dried over Na2SO4, and filtered. The solvent was evaporated under reduced pressure to yield the desired benzyl alcohol (B).General Procedure 9
[0121] LiAlD4 (3 mmol) or LiAlH4(3 mmol) was suspended in THF (6 mL) and cooled to 0 °C in an ice bath. A solution of ester (A) (1.07 g, 5 mmol ) in THF (1 mL) was addeddropwise via syringe. The reaction slurry was allowed to warm to room temperature overnight and then quenched by the subsequent addition of 15 mL EtOAc and after 30 min of H2O (3 x 5 mL). The white suspension was filtered and the residue washed with DCM (6 x 50 mL). The solution was dried over MgSCh and the solvent was removed under reduced pressure to yield benzyl alcohol (B).General Procedure 10
[0122] A solution of l,3,5-tris(2,2'-dipyridylamino)benzene (TDAB) (1 mmol) in THF (2 mL) was added dropwise to a solution of benzyl alcohol (A) (1 mmol), 5-hydroxyisoindolin- 1-one (B) (1 mmol) and triphenylphosphine (0.263 g, 1 mmol) in THF (10 mL). The resulting mixture was stirred at rt for 1 h, and then evaporated to give crude aryl bromide (C). The residue was purified by flash column chromatography on silica to give the desired product (C).General Procedure 11
[0123] To a solution of carboxylic acid (A) (0.43 mmol) in ACN (10 mL) was added ester(B) (0.52 mmol), HATU (198 mg, 0.52 mmol) and NMM (131 mg, 0.86 mmol). The mixture was stirred at room temperature for 16 hrs. The reaction mixture was concentrated and purified by flash column chromatography (silica gel, eluting with 5% DCM / ethanol) to afford desired product (C).Example 1: Synthesis of 4-Chloro-[l,l'-biphenyl]-3,3'-dicarboxylic acid
[0124] 5 -Borono-2-chlorobenzoic acid (0.3 g, 1.5 mmol), 3 -bromobenzoic acid (0.2 g, 1 mmol) Pd(dppf)C12 (0.073 g, 0.1 mmol) and 2M Na2COs (2 mL) were taken in DME (10 mL), the resulting mixture was heated at 80 °C for 2 h under an atmosphere of nitrogen, after completion of the reaction, the reaction mixture was cooled to rt, diluted with water and acidified using dil. HC1 and extracted using EtOAc (3 x 25 mL). The combined organic layer was washed with water, brine and dried over anhyd. Na2SO4. Removal of the solvent followed by reverse phase HPLC yielded the title compound. White solid (0.188 g, 63%). 'H NMR (400 MHz, DMSO-d6): 8 8.16 (s, 1H), 8.02 (s, 1H), 7.94 (t, J= 6.6 Hz, 2H), 7.83 (dd, J = 8.5, 2.1 Hz, 1H), 7.62-7.57 (m, 2H).Example 2: Synthesis of 4-Chloro-3'-formyl-[l,l'-biphenyl]-3-carboxylic acid
[0125] 3 -Bromobenzaldehyde (0.185 g, 1 mmol) 5-borono-2-chloro-benzoic acid (0.240 g, 1.2 mmol), and tetrakis(triphenylphosphine)palladium(0) (0.115 g, O.lmmol) were dissolved in DME (10 mL). To this solution was added 2 M Na2COs (2 mL), and the resulting mixture was heated at reflux under an atmosphere of N2 for 2 h. The reaction mixture was cooled to room temperature, and the solvents were removed in vacuo. The solvents were evaporated, and the residue was dissolved in water and neutralized using 1 M HC1. The aqueous layer was extracted with EtOAc, and the organic layer was dried over anhydrous Na2SO4. The solvent was evaporated in vacuo to obtain the crude acid as a yellow solid. The crude residue was purified using automated preparative HPLC to yield the desired compound as a white solid. (0.176 g, 67%).XH NMR (400 MHz, DMSO-d6): 6 10.06 (s, 1H), 8.20 (s, 1H), 8.07 (d, J= 1.8 Hz, 1H), 8.01 (d, J= 7.8 Hz, 1H), 7.90-7.85 (m, 2H), 7.68-7.58 (m, 2H).Example 3: Synthesis of 4-Chloro-3'-(hydroxymethyl)-[l,l'-biphenyl]-3-carboxylic acid
[0126] (3-Bromophenyl)methanol (0.187 g, 1 mmol) 5 -borono-2-chl oro-benzoic acid (0.300 g, 1.5 mmol), and tetrakis(triphenylphosphine)palladium(0) (0.115 g, O.lmmol) were dissolved in DME (10 mL). To this solution was added 2 M Na2COs (2 mL), and the resulting mixture was heated at reflux under an atmosphere of N2 for 2 h. The reaction mixture was cooled to room temperature. The solvents were removed in vacuo, and theresidue was dissolved in water and neutralized using 1 M HC1. The aqueous layer was extracted with EtOAc, and the organic layer was dried over anhydrous ISfeSC The solvent was evaporated in vacuo to obtain the crude acid as a yellow solid. The crude residue was purified using automated preparative HPLC to yield the desired compound as a white solid (0.198 g, 66%).1H NMR (400 MHz, DMSO-d6): 8 8.01 (d, J= 2.3 Hz, 1H), 7.79 (dd, J= 8.2, 2.3 Hz, 1H), 7.54 (d, J= 7.8 Hz, 1H), 7.63-7.59 (m, 4H), 7.42 (t, J= 7.6 Hz, 1H), 7.34 (d, J= 7.8 Hz, 1H), 4.52 (s, 2H).Example 4: Synthesis of 4-Chloro-3'-(((l-oxoisoindolin-5-yl)oxy)methyl)-[l,l'-biphenyl]- 3-carboxylic acidStep 1:
[0127] To a solution of 5-hydroxyisoindolin-l-one in (0.149 g, 1 mmol) ACN (30 mL) was added K2CO3 (0.276 g, 2 mmol), and methyl 3'-(bromomethyl)-4-chloro-[l,l'-biphenyl]-3- carboxylate (0.407g, 0.6 mmol) the mixture was heated at reflux for 1 h. The reaction mixture was filtered, and the solvent was evaporated under reduced pressure to obtain carboxylic ester (0.356 g, 85%).Step 2:
[0128] The carboxylic ester 0.061 g, 0.15 mmol) was dissolved in 1,2-di chloroethane and after addition of trimethyltinhydroxide (0.270 g, 1.5 mmol), the mixture was heated at 60-80 °C until LC-MS analysis indicated a complete reaction. After completion of the reaction, the mixture was concentrated in vacuo, and the residue was taken up in EtOAc (3 x 15 mL). The organic layer was washed with aqueous KHSO4 (0.01 N) or HC1 (5 %) (3 x 15 mL). The organic layer was then washed with brine (15 mL) and dried over sodium sulfate. Removal of the solvent followed by reverse phase HPLC afforded the product as a light yellow solid (0.03 g, 50%).1H-NMR (400 MHz, DMSO-d6) 6 8.29 (s, 1H), 8.02 (d, J= 2.7 Hz, 1H), 7.82- 7.79 (m, 2H), 7.65-7.47 (m, 5H), 7.19 (s, 1H), 7.09 (d, J= 8.7 Hz, 1H), 5.23 (s, 2H), 4.27 (s, 2H). LC-MS m / z [M+H]+found: 394.00.Example 5: Synthesis of 4-Chloro-3'-(((2-(cyclopentyl-2,2,5,5-d4)-l-oxoisoindolin-5- yl)oxy)methyl)-[l,l'-biphenyl]-3-carboxylic acid (Compound 1)Step 1:
[0129] At room temperature, to a cyclopentanone-d4 (0.250 g, 2.836 mmol) DCM solution (15 mL) was added Ti(OiPr)4 (0.806 g, 2.836 mmol), followed by the addition of benzylamine (0.303 g, 2.836 mmol). The reaction mixture was stirred for 1 hour and the solvent was removed. The residue was dissolved into MeOH (25 mL) and cooled to 0 °C. Then NaBD4 (0.310 g, 8.009 mmol) was slowly added to this solution and the reaction mixture was warmed up to room temperature and stirred for 2 hours. Then, the solvent was removed and the residue was purified by flash silica gel chromatography (DCMZEtOAc) to give the desired amine product N-benzylcyclopentanamine d4 as yellow oil. The above oil was dissolved in methanol (10 mL) and hydrogenated (1 atm of H2) in presence of Pd / C at rt for 12 h. Reaction mixture was passed through a short pad of celite and washed with methanol 3 times. Removal of the methanol gave the amine as a pale-yellow liquid (0.100 g,40%).Step 2:,
[0130] To a stirred solution of methyl 2-(bromomethyl)-4-methoxybenzoate (0.2 g, 0.771 mmol) in ACN (5 mL) was added cyclopentan-2, 2, 5, 5-d4-l-amine (0.068 g, 0.771 mmol) followed by potassium carbonate (0.213 g, 1.5 mmol). The resulting mixture was heated at 80 °C for 12 h. Cooled to rt, excess solvent was removed under vacuum and diluted with water and EtOAc. Organic layer collected, and aqueous layer was extracted three times with EtOAc (3 x 10 mL). Combined organic layer was washed with water, brine and dried over anhyd. sodium sulfate. Removal of the solvent followed by column chromatography (Hexanes: EtOAc (40%) yielded the desired compound as a white solid.
[0131] The above compound was taken in dry DCM (50 mL) and cooled in an ice bath, under N2 atmosphere. To the cooled mixture, IM BB solution (1.54 mL) in DCM (5 mL) was added dropwise and the resulting mixture was gradually warmed to rt and stirred at that tempfor 12 h. Reaction mixture was carefully quenched by the addition of water and stirred at room temperature for 1 h. After that the solvent was removed under reduced pressure and the crude material thus obtained was re-dissolved in minimum amount of MeOH (1 mL), and excess water was added and vigorously stirred. The precipitate thus formed was collected by filtration, washed with water and dried under vacuum to yield the desired compound as an off white solid (0.130 g, 76%).Step 3:(Compound 1)
[0132] To a solution of 2-(cyclopentyl-2,2,5,5-d4)-5-hydroxyisoindolin-l-one (80 mg) and K2CO3 (99 mg) in ACN (10 mL), was added methyl 3'-(bromomethyl)-4-chlorobiphenyl-3- carboxylate (123 mg). The resulting mixture was heated at reflux for 2 h. The reaction mixture was filtered, and the solvent was evaporated in vacuo to obtain methyl ester as a white solid (Quantitative).
[0133] Crude ester (0.172 g)) was dissolved in tetrahydrofuran (10 mL), 2M LiOH (0.9 mL) was added and the mixture was heated at reflux for 30 min. The solvent was evaporated and the residue was dissolved in water and acidified using 2M HC1. The aqueous layer was extracted with EtOAc (3 x 10 mL) and the combined organic layer was washed with water, brine and dried over anhydrous Na2SO4. The solvent was evaporated in vacuo to obtain the crude acid as a yellow solid. The crude residue was purified by reverse phase column chromatography (Acetonitrile; H2O solvent system) to give the title compound as a white solid (0.105 g). 'H-NMR (400 MHz, CDCI3) 8 8.19 (d, J= 2.3 Hz, 1H), 7.82 (d, J= 8.7 Hz, 1H), 7.65-7.42 (m, 6H), 7.08-7.01 (m, 2H), 6.29 (brs, 1H), 5.17 (s, 2H), 4.74-4.71 (m, 1H), 4.31 (s, 2H), 1.77-1.62 (m, 4H). LC-MS m / z calcd. for C27H20D4CINO4 [M+H]+466.16; found: 466.15.Example 6: Synthesis of 4-Chloro-3'-(((2-(cyclopentyl-3,3,4,4-d4)-l-oxoisoindolin-5- yl)oxy)methyl)-[l,l'-biphenyl]-3-carboxylic acid (Compound 2)(Compound 2)
[0134] To a solution of 2-(cyclopentyl-3,3,4,4-d4)-5-hydroxyisoindolin-l-one (0.088 g, 0.4 mmol) and K2CO3 (0.110 g, 0.8 mmol) in ACN (10 mL), was added methyl 3'- (bromomethyl)-4-chlorobiphenyl-3-carboxylate (0.135 g, 0.4 mmol). The resulting mixture was heated at reflux for 2 h. The reaction mixture was filtered and the solvent was evaporated in vacuo to obtain intermediate methyl ester as a white solid (Quantitative).
[0135] Crude ester (0.191 mg, 0.4 mmol)) was dissolved in tetrahydrofuran (10 mL), 2M LiOH (1 mL, 2 mmol) was added and the mixture was heated at reflux for 30 min. The solvent was evaporated and the residue was dissolved in water and acidified using 2M HC1. The aqueous layer was extracted with EtOAc (3 x 10 mL) and the combined organic layer was washed with water, brine and dried over anhydrous Na2SO4. The solvent was evaporated in vacuo to obtain the crude acid as a yellow solid. The crude residue was purified by reverse phase column chromatography (Acetonitrile; H2O solvent system) to give the title compound as a white solid (0.115 g, 62%). ‘H-NMR (400 MHz, DMSO-d6) 8 8.01 (d, J= 2.3 Hz, 1H), 7.82-7.79 (m, 2H), 7.67-7.46 (m, 5H), 7.20 (d, J= 1.8 Hz, 1H), 7.09 (dd, J= 8.2, 2.3 Hz, 1H), 5.23 (s, 2H), 4.48 (t, J= 8.0 Hz, 1H), 4.35 (s, 2H), 1.80 1.78 (m, 2H), 1.61-1.55 (m, 2H). LC-MS m / z calcd. for C27H20D4CINO4 [M+H]+466.16; found: 466.15.Example 7: Synthesis of 4-Chloro-3'-(((2-(cyclopentyl-l,2,2,5,5-d5)-l-oxoisoindolin-5- yl)oxy)methyl)-[l,l'-biphenyl]-3-carboxylic acid (Compound 3)
[0136] To a solution of 2-(cyclopentyl-l, 2,2,5, 5-d5)-5-hydroxyisoindolin-l-one (0.111 g, 0.499 mmol, prepared according to a similar procedure described for cyclopentan-2, 2,5, 5-d4- 1-amine using CD3OD as the solvent for NaBD4 reduction) and K2CO3 (0.138 g, 0.999 mmol) in ACN (10 mL), was added methyl 3'-(bromomethyl)-4-chlorobiphenyl-3-carboxylate (0.170 g, 0.499 mmol). The resulting mixture was heated at reflux for 2 h. The reaction mixture was filtered and the solvent was evaporated in vacuo to obtain intermediate methyl ester as a white solid (Quantitative).
[0137] Crude ester (0.240 g, 0.5 mmol) was dissolved in tetrahydrofuran (10 mL), 2M LiOH (1.25 mL, 2.5 mmol) was added and the mixture was heated at reflux for 30 min. The solvent was evaporated and the residue was dissolved in water and acidified using 2M HC1. The aqueous layer was extracted with EtOAc (3 x 10 mL) and the combined organic layer was washed with water, brine and dried over anhydrous Na2SO4. The solvent was evaporated in vacuo to obtain the crude acid as a yellow solid. The crude residue was purified by reverse phase column chromatography (ACN; H2O solvent system) to give the title compound as a white solid (0.185 g, 79%). 'H-NMR (400 MHz, DMSO-d6) 8 8.01 8.01 (d, J= 2.3 Hz, 1H), 7.87-7.79 (m, 2H), 7.68-7.47 (m, 6H), 7.20 (d, J= 1.4 Hz, 1H), 7.09 (dd, J= 8.2, 2.3 Hz, 1H), 5.23 (s, 2H), 4.35 (s, 2H), 1.69-1.64 (m, 2H), 1.55-1.50 (m, 2H) LC-MS m / z calcd. for C27HI9D5C1NO4[M+H]+467.17; found 467.15.Example 8: Synthesis of 4-Chloro-3'-(((2-cyclopentyl-l-oxoisoindolin-5-yl)oxy)methyl-d)- [l,l'-biphenyl]-3-carboxylic acid (Compound 4)Step 1:
[0138] NaBD4(0.1 g, 3 mmol) was added to a solution of 3 -bromobenzaldehyde (0.4 g, 2 mmol) in methanol (5 mL) at 0 °C. The resulting mixture was stirred at 0 °C for 1 h. The mixture was quenched by the addition of water and the solvent was evaporated under reduced pressure. The water layer was extracted with EtOAc (3 x 30 mL). The organic layers were combined, dried over Na2SO4, and filtered. The solvent was evaporated under reduced pressure to yield 3-bromophenyl)methan-d-ol as a colorless liquid (0.37 g, 93%).Step 2:
[0139] A solution of TDAB (0.23 g, 1 mmol) in THF (2 mL) was added dropwise to a solution of (3-bromophenyl)methan-d-ol (0188 g, 1 mmol), 2-cyclopentyl-5- hydroxyisoindolin-l-one (0.217 g,l mmol) and triphenylphosphine (0.263 g, 1 mmol) in THF (10 mL). The resulting mixture was stirred at rt for 1 h, and then evaporated to give crude 5-((3-bromophenyl)methoxy-d)-2-cyclopentylisoindolin-l-one. The residue was purified by flash column chromatography on silica gel (eluent hexane-EtOAc, hexane to 30% EtOAc in hexanes) to afford 5-((3-bromophenyl)methoxy-d)-2-cyclopentylisoindolin-l-one as a pale yellow solid (0.3 g, 78%).Step 3:(Compound 4)
[0140] 5-((3-Bromophenyl)methoxy-d)-2-cyclopentylisoindolin-l-one (0.387 g, 1 mmol), 5- borono-2-chlorobenzoic acid (0.300 g,l .5 mmol) and tetrakistriphenylphosphinepalladium(O) (0.115 g, 0.1 mmol) were taken in DME (20 mL). To this 2M Na2CC>3 solution (2 mL) was added and the resulting solution was refluxed in an atmosphere of N2 for 2 h. The reaction mixture was cooled to room temperature and diluted with water and then acidified using IN HC1. The product was extracted with EtOAc (3 x 25 mL) and washed with brine and the organic layer was dried over anhydrous Na2SO4. The solvent was evaporated in vacuum to obtain the crude product. The crude product was purified using automated prep-HPLC to yield the desired compound as a white solid (0.31 g, 67%).1H-NMR (400 MHz, DMSO-d6) 8 8.01 (d, J= 2.7 Hz, 1H), 7.81-7.78 (m, 2H), 7.66- 7.63 (m, 1H), 7.60 (d, J= 8.2 Hz, 1H), 7.54-7.47 (m, 3H), 7.19 (d, J= 1.8 Hz, 1H), 7.08 (dd, J= 8.2, 2.3 Hz, 1H), 5.21 (s, 1H), 4.50-4.48 (m 1H), 4.34 (s, 2H), 1.81-1.54 (m, 8H). LC-MS m / z [M+H]+found: 463.15.Example 9: Synthesis of 4-Chloro-3'-(((2-cyclopentyl-l-oxoisoindolin-5-yl)oxy)methyl- d2)-[l,l'-biphenyl]-3-carboxylic acid (Compound 5)Step 1:
[0141] LiAlD4 (0.129 g, 3 mmol) was suspended in THF (6 mL) and cooled to 0 °C in an ice bath. A solution of methyl 3 -bromobenzoate (1.07 g, 5 mmol ) in THF (1 mL) was added dropwise via syringe. The reaction slurry was allowed to warm to room temperature overnight and then quenched by the subsequent addition of EtOAc (15 mL) and after 30 min of H2O (3 x 5 mL). The white suspension was filtered and the residue washed with DCM (6 x50 mL). The filtrate was dried over MgSCh and the solvent was removed under reduced pressure to yield 3-bromophenyl)methan-d2-ol. Colorless viscous liquid (0.89 g, 94%).
[0142] Step 2:
[0143] A solution of TDAB (0.23 g, 1 mmol) in THF (2 mL) was added dropwise to a solution of (3-bromophenyl)methan-d2-ol (0.189 g, 1 mmol), 2-cyclopentyl-5- hydroxyisoindolin-l-one (0.217 g ,1 mmol) and triphenylphosphine (0.263g, 1 mmol) in THF (2 mL) under stirring at rt for 1 h, and then evaporated to afford crude 5-((3- bromophenyl)methoxy-d2)-2-cyclopentylisoindolin-l-one. The residue was purified by flash column chromatography on silica gel (eluent hexane-EtOAc) to afford 5-((3- bromophenyl)methoxy-d2)-2-cyclopentylisoindolin-l-one as a pale yellow solid (0.288 g,74%).Step 3:
[0144] 5-((3-Bromophenyl)methoxy-d2)-2-cyclopentylisoindolin-l-one (0.288 g, 0.742 mmol), 5-borono-2-chlorobenzoic acid (0.223 g, 1.11 mmol) and tetrakistriphenylphosphinepalladium(O) (0.085 g, 0.074 mmol) were taken in DME (10 mL). The mixture was treated with 2M Na2COs solution (2 mL) and the resulting solution was refluxed in an atmosphere of N2 for 2 h. The reaction mixture was cooled to room temperature and diluted with water and then acidified using IN HC1. The aqueous mixture was extracted with EtOAc (3 x 20 mL) and washed with brine and the organic layer was dried over anhydrous Na2SO4. The solvent was evaporated in vacuum to obtain the crude product. The crude product was purified using automated prep-HPLC to yield the desired compound as a white solid (0.218 g, 63%).1H-NMR (400 MHz, DMSO-d6) 8 8.02 (d, J= 2.7 Hz, 1H), 7.80 (dd, J= 8.2, 2.3 Hz, 1H), 7.66-7.30 (m, 6H), 7.19 (d, J= 1.8 Hz, 1H), 7.08 (dd, J= 8.2, 2.3 Hz, 1H), 4.49-4.46 (m, 1H), 4.34 (s, 2H), 1.83-1.53 (m, 8H). LC-MS m / z [M+H]+found: 464.00.Example 10: Synthesis of 4-Chloro-3'-(((2-(3-hydroxycyclopentyl)-l-oxoisoindolin-5- yl)oxy)methyl)-[l,l'-biphenyl]-3-carboxylic acid (Compound 6)
[0145] IM BH3 THF ( 0.8 mL) complex was added via syringe to a solution of methyl 4- chloro-3'-(((2-(cyclopent-3-en-l-yl)-l-oxoisoindolin-5-yl)oxy)methyl)-[l,l'-biphenyl]-3- carboxylate (0.350 g, 0.738 mmol) in THF (5 mL). The resulting mixture was stirred at rt for 45 mins. After that time a few drops of acetone was added to the reaction mixture and stirred for 2 min., then a few drops of water followed by 3 M NaOH (0.3 mL) and 30% H2O2 (0.3 mL) were added to the same reaction mixture and the resulting mixture was heated at 60 °C for 30 min. The reaction mixture was cooled to rt and saturated brine was added to the reaction. Organic layer was collected, washed with water, brine and dried over Na2SO4 and evaporated to give the crude ester, which was redissolved in dioxane and heated at 50 °C in presence of 2M LiOH solution (1.8 mL). After cooled to rt, reaction mixture diluted with water, acidified using 2N HC1 and extracted with EtOAc. Removal of the solvent followed by reverse phase HPLC yielded the corresponding acid as a white solid (0.238 g, 67%). LC-MS m / z calcd. for C27H24CINO5 [M+H]+478.13; found: 478.10.Example 11: Synthesis of 4-Chloro-3'-(((2-(cyclopent-3-en-l-yl)-l-oxoisoindolin-5- yl)oxy)methyl)-[l,l'-biphenyl]-3-carboxylic acid (Compound 12)(Compound 12)
[0146] 2-(Cyclopent-3-en-l-yl)-5-hydroxyisoindolin-l-one (0.4000 g, 1.858 mmol), methyl 3'-(bromomethyl)-4-chloro-[l,l'-biphenyl]-3-carboxylate (0.631 g 1.858 mmol) potassium carbonate (0.513 g, 2 mmol) were taken in ACN (50 mL). The mixture was stirred at 80 °C for 2 hrs. The solid was filtered off and the solvent was removed to afford crude ester as a pale yellow solid. To a solution of carboxylic acid methyl ester in dioxane / ELO (5: 1, 20 mL), 2M LiOH (4.7 mL) was added. The mixture was stirred at 60 °C for 4 h. The reaction was cooled to rt, diluted with water and acidified with IN HC1 to pH 2 and extracted with EtOAc (3 x 25 mL). The solvent was removed the residue was purified with C18 reverse phasecolumn to afford the desired product as a white solid. 'H-NMR (400 MHz, DMSO-de) 8 8.01 (d, J= 2.3 Hz, 1H), 7.82-7.78 (m, 2H), 7.66-7.47 (m, 5H), 7.20 (d, J= 2.3 Hz, 1H), 7.09 (dd, J= 8.2, 2.3 Hz, 1H), 5.77 (s, 2H), 5.23 (s, 2H), 4.95-4.91 (m, 1H), 4.21 (s, 2H), 2.63-2.50 (m, 2H), 2.36-2.29 (m, 2H). ). LC-MS m / z [M+H]+460.10.Example 12: Synthesis of 4-Chloro-3'-(((2-(2-hydroxycyclopentyl)-l-oxoisoindolin-5- yl)oxy)methyl)-[l,l'-biphenyl]-3-carboxylic acid (Compound 8)Scheme:Methyl 2-chloro-5-iodobenzoate
[0147] To a solution of 2 -chi oro-5 -iodobenzoic acid (10 g, 35.4 mmol) in MeOH (100 mL) was added SOCh (8.4 g, 70.8 mmol) at 0 °C. The mixture was stirred at 80 °C for 16 hrs. The reaction mixture was concentrated and diluted with EtOAc (60 mL). The mixture was washed with water (3 x 20 mL) and brine (20 mL), dried over ISfeSCL and filtered. The filtrate was concentrated and purified by flash column chromatography (silica gel, eluting with PE) to afford methyl 2-chloro-5-iodobenzoate (10 g, 95%) as a white solid. HPLC / UV purity: 90%; LC-MS (ESI): 296.2 (M+H)+.Methyl 4-chloro-3'-methyl-[l,l'-biphenyl]-3-carboxylate
[0148] The mixture of methyl 2-chloro-5-iodobenzoate (7 g, 23.61 mmol), m-tolylboronic acid (3.85 g, 28.33 mmol), Pd(PPhs)4 (2.73 g, 2.36 mmol) and ISfeCCL (5 g, 47.2 mmol) in dioxane (100 mL) and H2O (10 mL) was stirred at 70 °C for 16 hrs under N2. The reaction mixture was concentrated and purified by flash column chromatography (silica gel, eluting with 2% EA / PE) to afford methyl 4-chl oro-3 '-methyl-[l,l'-biphenyl]-3 -carboxylate (5 g, 81%) as a colorless oil. HPLC / UV purity: 90%; LC-MS (ESI): 261.2 (M+H)+.Methyl 3'-(bromomethyl)-4-chloro-[l,l'-biphenyl]-3-carboxylate
[0149] To a solution of methyl 4-chloro-3'-methyl-[l,l'-biphenyl]-3-carboxylate (5 g, 19.2 mmol) in CCI4 (80 mL) were added NBS (5.1 g, 28.8 mmol) and AIBN (315 mg, 1.92 mmol). The mixture was stirred at 80 °C for 18 hrs. The reaction mixture was concentrated and then extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with water (30 mL) and brine (30 mL), dried over Na2SO4 and filtered. The filtrate was concentrated and purified by flash column chromatography (silica gel, eluting with 9% DCM / PE) to afford methyl 3'-(bromomethyl)-4-chloro-[l,l'-biphenyl]-3-carboxylate (5.4 g, 83%) as a white solid. HPLC / UV purity: 95%; LC-MS (ESI): 339.0(M+H)+.2-(2-hydroxycyclopentyl)-5-methoxyisoindolin-l-one
[0150] To a solution of methyl 2-(bromomethyl)-4-methoxybenzoate (200 mg, 0.77 mmol) in ACN (5 mL) were added 2-aminocyclopentan-l-ol (86 mg, 0.85 mmol) and potassium carbonate (213 mg, 1.54 mmol). The mixture was stirred at 80 °C for 16 hrs. The reaction mixture was concentrated and then extracted with DCM (3 x 10 mL). The combined organic layers were washed with water (30 mL) and brine (30 mL), dried over Na2SO4 and filtered.The filtrate was concentrated and purified by flash column chromatography (silica gel, eluting with 66% EtOAc / PE) to afford 2-(2-hydroxycyclopentyl)-5-methoxyisoindolin-l-one (130 mg, 68%) as a white solid. HPLC / UV purity: 90%; LC-MS (ESI): 248.2 (M + 1)+.5-hydroxy-2-(2-hydroxycyclopentyl)isoindolin-l-one
[0151] To a solution of 2-(2-hydroxycyclopentyl)-5-methoxyisoindolin-l-one (130 mg, 0.52 mmol) in DCM (8 mL) was added a solution of BBrs (IN, 2.6 mL, 2.6 mmol) in DCM drop wise at 0 °C under N2. The mixture was stirred at room temperature for 16 hrs. The reaction mixture was quenched with ice water (30 mL) and then extracted with DCM (3 x 10 mL). The combined organic layers were washed with water (30 mL) and brine (30 mL), dried over Na2SO4, and filtered. The filtrate was concentrated and purified by flash column chromatography (silica gel, eluting with 6% CH3OH / DCM) to afford 5-hydroxy-2-(2- hydroxycyclopentyl)isoindolin-l-one (80 mg, 65%) as a white solid. HPLC / UV purity: 90%; LC-MS (ESI): 233.8 (M+H)+.Methyl 4-chloro-3'-(((2-(2-hydroxycyclopentyl)-l-oxoisoindolin-5-yl)oxy)methyl)-[l,l'- biphenyl] -3-carboxylate
[0152] To a solution of 5-hydroxy-2-(2-hydroxycyclopentyl)isoindolin-l-one (80 mg, 0.33 mmol) in DMF (2 mL) were added methyl 3'-(bromomethyl)-4-chloro-[l,l'-biphenyl]-3- carboxylate (102 mg, 0.3 mmol) and potassium carbonate (62 mg, 0.45 mmol). The mixture was stirred at 60 °C for 18 hrs. The reaction mixture was quenched with water (20 mL), and then extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with water (30 mL) and brine (30 mL), dried over Na2SO4 and filtered. The filtrate was concentrated and purified by flash column chromatography (silica gel, eluting with 50% EtOAc / DCM) to afford methyl 4-chloro-3'-(((2-(2-hydroxycyclopentyl)-l-oxoisoindolin-5- yl)oxy)methyl)-[l,l'-biphenyl]-3-carboxylate (65 mg, 44%) as a colorless oil. HPLC / UV purity: 95%; LC-MS (ESI): 492.0 (M + 1)+.4-chloro-3'-(((2-(2-hydroxycyclopentyl)-l-oxoisoindolin-5-yl)oxy)methyl)-[l,l'- biphenyl] -3-carboxylic acid( Compound 8)
[0153] To a solution of methyl 4-chloro-3'-(((2-(2-hydroxycyclopentyl)-l-oxoisoindolin-5- yl)oxy)methyl)-[l,l'-biphenyl]-3-carboxylate (60 mg, 0.12 mmol) in THF (1 mL) and H2O (1 mL) was added LiOHH2O (20 mg, 0.48 mmol). The mixture was stirred at room temperature for 16 hrs. The reaction mixture was concentrated and acidified to pH=4 with HC1 aqueous (IN). Then the mixture was filtered and the precipitate was dried in vacuo to afford 4-chloro- 3 '-(((2-(2 -hydroxy cyclopentyl)- 1 -oxoisoindolin-5-yl)oxy)methyl)-[ 1 , 1 '-biphenyl]-3 - carboxylic acid (25 mg, 44%) as a white solid. HPLC / UV purity: 100%; LC-MS (ESI): 478.2 (M + 1)+. ‘HNMR (400 MHz, DMSO-tL) 513.54 (s, 1H), 8.05 (d, J= 2.0 Hz, 1H), 7.86 - 7.83 (m, 2H), 7.69 (d, J= 3.6 Hz, 1H), 7.64 (d, J= 8.4 Hz, 1H), 7.58 (d, J= 8.4 Hz, 1H), 7.55- 7.51 (m, 2H), 7.25 (s, 1H), 7.13 (dd, J= 8.4, 2.0 Hz, 1H), 5.28 (s, 2H), 4.91 (s, 1H), 4.40 (s, 2H), 4.24 - 4.18 (m, 1H), 4.13 - 4.09 (m, 1H), 1.92 - 1.80 (m, 2H), 1.74 - 1.62 (m, 3H), 156- 1.49 (m, 1H).Example 13: Synthesis of 4-chloro-3'-(((2-(4-hydroxycyclopent-2-en-l-yl)-l- oxoisoindolin-5-yl)oxy)methyl)-[l,l'-biphenyl]-3-carboxylic acid (Compound 11)Scheme:Methyl 4-chloro-3'-(((2-(cyclopent-2-en-l-yl)-l-oxoisoindolin-5-yl)oxy)methyl)-[l,l'- biphenyl] -3-carboxylate
[0154] To a solution of methyl 4-chloro-3'-(((2-(2-hydroxycyclopentyl)-l-oxoisoindolin-5- yl)oxy)methyl)-[l,l'-biphenyl]-3-carboxylate (400 mg, 0.81 mmol) in toluene (50 mL) was added TsOH (139 mg, 0.81 mmol). The mixture was stirred at 120 °C for 16 hrs using Dean- Stark trap. The reaction mixture was concentrated and purified by flash column chromatography (silica gel, eluting with 33% EtOAc / PE) to afford methyl 4-chloro-3'-(((2- (cyclopent-2-en- 1 -yl)- 1 -oxoisoindolin-5-yl)oxy)methyl)-[ 1 , 1 '-biphenyl]-3 -carboxylate (190 mg, 49%) as a white solid. HPLC / UV purity: 90%; LC-MS (ESI): 474.2 (M+H)+.Methyl 4-chloro-3'-(((2-(4-hydroxycyclopent-2-en-l-yl)-l-oxoisoindolin-5- yl)oxy)methyl)- [1 , 1 '-biphenyl] -3-carboxylate
[0155] To a solution of methyl 4-chloro-3'-(((2-(cyclopent-2-en-l-yl)-l-oxoisoindolin-5- yl)oxy)methyl)-[l,l'-biphenyl]-3-carboxylate (190 mg, 0.4 mmol) in dioxane / pyridine / EEO (450: 10: 1) (10 mL) was added SeCL (89 mg, 0.8 mmol). The mixture was stirred at 100 °C for 16 hrs in sealed tube under N2. The reaction mixture was concentrated and then extracted with EtOAc (3 x 5 mL). The combined organic layers were washed with water (30 mL) and brine (30 mL), dried over ISfeSCU and filtered. The filtrate was concentrated and purified by flash column chromatography (silica gel, eluting with 50% EA / DCM) to afford methyl 4- chl oro-3 '-(((2-(4-hydroxycy cl opent-2-en- 1 -yl)- 1 -oxoisoindolin-5-yl)oxy)methyl)-[ 1,1'- biphenyl]-3-carboxylate (17 mg, 9%) as a brown oil. HPLC / UV purity: 90%; LC-MS (ESI): 490.2 (M+H)+.4-chloro-3'-(((2-(4-hydroxycyclopent-2-en-l-yl)-l-oxoisoindolin-5-yl)oxy)methyl)-[l,l'- biphenyl]-3-carboxylic acid (Compound 11)
[0156] To a solution of methyl 4-chl oro-3 '-(((2-(4-hydroxycy cl opent-2-en-l -yl)-l- oxoisoindolin-5-yl)oxy)methyl)-[l,l'-biphenyl]-3-carboxylate (35 mg, 0.07 mmol) in THF (2 mL) and H2O (2 mL) was added LiOHH2O (12 mg, 0.28 mmol). The mixture was stirred at room temperature for 16 hrs. The reaction mixture was concentrated and acidified to pH=4 with HC1 aqueous (IN). Then the mixture was filtered and the precipitated was dried toafford 4-chloro-3'-(((2-(4-hydroxycyclopent-2-en-l-yl)-l-oxoisoindolin-5-yl)oxy)methyl)- [l,l'-biphenyl]-3 -carboxylic acid (20 mg, 59%) as a white solid. HPLC / UV purity: 100%; LC-MS (ESI): 476.2 (M + 1)+. *HNMR (400 MHz, CD3OD) 5 7.99 (d, J= 2.4 Hz, 1H), 7.71 - 7.65 (m, 3H), 7.61 - 7.58 (m, 1H), 7.53 (d, J= 8.4 Hz, 1H), 7.48 - 7.47 (m, 2H), 7.17 (d, J = 1.6 Hz, 1H), 7.14 (dd, J= 8.4, 2.4 Hz, 1H), 6.12 (dt, J= 5.6, 2.0 Hz, 1H), 5.91 - 5.90 (m, 1H), 5.62 - 5.60 (m, 1H), 5.24 (s, 2H), 5.05 - 5.04 (m, 1H), 4.25 (q, J= 13.2 Hz, 2H), 2.18 - 2.12 (m, 2H).Example 14: Synthesis of 4-chloro-3'-(((2-(cyclopent-2-en-l-yl)-l-oxoisoindolin-5- yl)oxy)methyl)-[l,l'-biphenyl]-3-carboxylic acid (Compound 10)
[0157] To a solution of methyl 4-chloro-3'-(((2-(cyclopent-2-en-l-yl)-l-oxoisoindolin-5- yl)oxy)methyl)-[l,l'-biphenyl]-3-carboxylate (43 mg, 0.09 mmol) in THF (1 mL) and H2O (1 mL) was added LiOHH2O (15 mg, 0.36 mmol). The mixture was stirred at room temperature for 16 hrs. The reaction mixture was concentrated and acidified to pH=4 with HC1 aqueous (IN). Then the mixture was filtered and the filter cake was dried to afford 4-chloro-3'-(((2- (cyclopent-2-en- 1 -yl)- 1 -oxoisoindolin-5-yl)oxy)methyl)-[ 1 , 1 '-biphenyl]-3 -carboxylic acid (22 mg, 53%) as a white solid. HPLC / UV purity: 100%; LC-MS (ESI): 460.0 (M + 1)+. 'H NMR (400 MHz, CD3OD) 5 8.03 (d, J= 2.4 Hz, 1H), 7.74 - 7.71 (m, 2H), 7.67 (d, J= 8.4 Hz, 1H), 7.61 - 7.59 (m, 1H), 7.55 (d, J= 8.4 Hz, 1H), 7.49 - 7.48 (m, 2H), 7.19 (d, J=1.2 Hz, 1H), 7.14 (dd, J= 8.4, 2.0 Hz, 1H), 6.14 - 6.12 (m, 1H), 5.73 - 5.71(m, 1H), 5.46 - 5.45 (m, 1H), 5.25 (s, 2H), 4.36 - 4.25 (m, 2H), 2.63 - 2.58 (m, 1H), 2.46 - 2.44 (m, 1H), 2.35 - 2.33 (m, 1H), 1.84 -1.82 (m, 1H).Example 15: Synthesis of (2S,3S,4S,5R)-6-((4-chloro-3'-(((2-cyclopentyl-l-oxoisoindolin- 5-yl)oxy)methyl)-[l,l'-biphenyl]-3-carbonyl)oxy)-3,4,5-trihydroxytetrahydro-2H-pyran- 2-carboxylic acid (Compound 14)Scheme:(Compound 14)Allyl (2S,3S,4S,5R)-3,4,5,6-tetrahydroxytetrahydro-2H-pyran-2-carboxylate
[0158] To a solution of (2S,3S,4S,5R)-3,4,5,6-tetrahydroxytetrahydro-2H-pyran-2-carboxylic acid (2 g, 10.3 mmol) in DMF (20 mL) was added DBU (1.7 g, 11.33 mmol). 3-bromoprop- 1-ene (1.5 g, 12.36 mmol) was added drop wise and the mixture was stirred at room temperature for 16 hrs after the resulting solution was stirred for 15 min at room temperature. The reaction mixture was concentrated and purified by flash column chromatography (silica gel, eluting with 50% toluene / acetone) to afford allyl (2S,3 S,4S,5R)-3, 4,5,6- tetrahydroxytetrahydro-2H-pyran-2-carboxylate (2 g, 83%) as a yellow solid. HPLC / UV purity: 90%.Allyl (2S,3S,4S,5R)-6-((4-chloro-3'-(((2-cyclopentyl-l-oxoisoindolin-5-yl)oxy)methyl)- [l,l'-biphenyl]-3-carbonyl)oxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylate
[0159] To a solution of 4-chloro-3'-(((2-cyclopentyl-l-oxoisoindolin-5-yl)oxy)methyl)-[l,l'- biphenyl]-3-carboxylic acid (200 mg, 0.43 mmol) in ACN (10 mL) were added allyl (2S,3S,4S,5R)-3,4,5,6-tetrahydroxytetrahydro-2H-pyran-2-carboxylate (122 mg, 0.52 mmol), HATU (198 mg, 0.52 mmol) and NMM (131 mg, 0.86 mmol). The mixture was stirred at room temperature for 16 hrs. The reaction mixture was concentrated and purified by flash column chromatography (silica gel, eluting with 5% DCM / ethanol) to afford allyl (2S,3S,4S,5R)-6-((4-chloro-3'-(((2-cyclopentyl-l-oxoisoindolin-5-yl)oxy)methyl)-[l,T- biphenyl]-3-carbonyl)oxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylate (140 mg, 48%) as a brown oil. HPLC / UV purity: 90%; LC-MS (ESI): 678.2 (M + 1)+.(2S,3S,4S,5R)-6-((4-chloro-3'-(((2-cyclopentyl-l-oxoisoindolin-5-yl)oxy)methyl)-[l,l'- biphenyl]-3-carbonyl)oxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid (Compound 14)
[0160] To a solution of allyl (2S,3S,4S,5R)-6-((4-chloro-3'-(((2-cyclopentyl-l-oxoisoindolin- 5-yl)oxy)methyl)-[l,l'-biphenyl]-3-carbonyl)oxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2- carboxylate (80 mg, 0.12 mmol) in THF (1.5 mL) was added Pd(PPh3)4 (14 mg, 0.012 mmol) at 0 °C followed by pyrrolidine (9 mg, 0.12 mmol). The mixture was stirred at 0 °C for 30 min. The reaction mixture was concentrated and purified with prep-HPLC to afford (2S,3S,4S,5R)-6-((4-chloro-3'-(((2-cyclopentyl-l-oxoisoindolin-5-yl)oxy)methyl)-[l,T- biphenyl]-3-carbonyl)oxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid (10.7 mg, 14%) as a white solid. HPLC / UV purity: 100%; LC-MS (ESI): 638.2 (M + 1)+. 'H NMR (400 MHz, CD3OD) 5 8.25 (s, 1H), 7.82 (dd, J= 8.4, 1.2 Hz, 1H), 7.77 (s, 1H), 7.67 (d, J= 8.4 Hz, 1H), 7.65 - 7.60 (m, 2H), 7.51 (d, J= 4.4 Hz, 2H), 7.22 (s, 1H), 7.15 (d, J= 8.4 Hz, 1H), 5.79 - 5.73 (m, 1H), 5.27 (s, 2H), 4.66 - 4.64 (m, 1H), 4.45 (s, 2H), 4.03 (d, J= 9.6 Hz, 1H), 3.62 - 3.59 (m, 1H), 3.56 - 3.53(m, 2H), 2.00 - 1.97 (m, 2H), 1.84 - 1.82 (m, 2H), 1.73 - 1.69 (m, 4H).Example 16: Synthesis of (2S,3S,4S,5R)-6-((4-chloro-3'-(((2-(2-hydroxycyclopentyl)-l- oxoisoindolin-5-yl)oxy)methyl)-[l,l'-biphenyl]-3-carbonyl)oxy)-3,4,5- trihydroxytetrahydro-2H-pyran-2-carboxylic acid (Compound 9)Scheme:(Compound 9)Methyl 4-chloro-3'-(((l-oxo-2-(2-((tetrahydro-2H-pyran-2-yl)oxy)cyclopentyl)isoindolin-5-yl)oxy)methyl)-[l,l'-biphenyl]-3-carboxylate
[0161] To a solution of methyl 4-chloro-3'-(((2-(2-hydroxycyclopentyl)-l-oxoisoindolin-5- yl)oxy)methyl)-[l,l'-biphenyl]-3-carboxylate (510 mg, 1.04 mmol) and TsOH (20 mg, 0.104 mmol) in DCM (20 mL) was added DHP (131 mg, 1.56 mmol). The mixture was stirred at room temperature for 16 hrs. The reaction mixture was extracted with DCM (3 x 15 mL). The combined organic layers were washed with water (50 mL) and brine (50 mL), dried over Na2SO4 and filtered. The filtrate was concentrated and purified by flash column chromatography (silica gel, eluting with 33% EtOAc / PE) to afford methyl 4-chloro-3'-(((l- oxo-2-(2-((tetrahydro-2H-pyran-2-yl)oxy)cyclopentyl)isoindolin-5-yl)oxy)methyl)-[l,l'- biphenyl]-3-carboxylate (400 mg, 67%) as a white solid. HPLC / UV purity: 90%; LC-MS (ESI): 492.2 (M - 84)+.4-chloro-3'-(((l-oxo-2-(2-((tetrahydro-2H-pyran-2-yl)oxy)cyclopentyl)isoindolin-5- yl)oxy)methyl)-[l,l'-biphenyl]-3-carboxylic acid
[0162] To a solution of methyl 4-chloro-3'-(((l-oxo-2-(2-((tetrahydro-2H-pyran-2- yl)oxy)cyclopentyl)isoindolin-5-yl)oxy)methyl)-[l,l'-biphenyl]-3-carboxylate (400 mg, 0.69 mmol) in THF (5 mL) and H2O (5 mL) was added LiOH LO (116 mg, 2.76 mmol). The mixture was stirred at room temperature for 16 hrs. The reaction mixture was concentrated and acidified to pH=4 with HC1 aqueous (IN). Then the mixture was filtered and the precipitate was dried to afford 4-chloro-3'-(((l-oxo-2-(2-((tetrahydro-2H-pyran-2- yl)oxy)cyclopentyl)isoindolin-5-yl)oxy)methyl)-[l,l'-biphenyl]-3-carboxylic acid (360 mg, 92%) as a light yellow solid. HPLC / UV purity: 90%; LC-MS (ESI): 478.3 (M - 84)+.Allyl (2S,3S,4S,5R)-6-((4-chloro-3'-(((l-oxo-2-(2-((tetrahydro-2H-pyran-2- yl)oxy)cyclopentyl)isoindolin-5-yl)oxy)methyl)-[l,l'-biphenyl]-3-carbonyl)oxy)-3,4,5- trihydroxytetrahydro-2H-pyran-2-carboxylate
[0163] To a solution of 4-chloro-3'-(((l-oxo-2-(2-((tetrahydro-2H-pyran-2- yl)oxy)cyclopentyl)isoindolin-5-yl)oxy)methyl)-[l,l'-biphenyl]-3-carboxylic acid (160 mg, 0.28 mmol) in ACN (15 mL) were added allyl (2S,3S,4S,5R)-3,4,5,6-tetrahydroxytetrahydro- 2H-pyran-2-carboxylate (80 mg, 0.34 mmol), HATU (129 mg, 0.34 mmol) and NMM (57 mg, 0.56 mmol). The mixture was stirred at room temperature for 3 hrs. The reaction mixture was concentrated and purified by flash column chromatography (silica gel, eluting with 5% DCM / ethanol) to afford allyl (2S,3S,4S,5R)-6-((4-chloro-3'-(((l-oxo-2-(2-((tetrahydro-2H- pyran-2-yl)oxy)cyclopentyl)isoindolin-5-yl)oxy)methyl)-[l,l'-biphenyl]-3-carbonyl)oxy)- 3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylate (50 mg, 22%) as a white solid.HPLC / UV purity: 90%; LC-MS (ESI):694.2 (M - 84)+.Allyl (2S,3S,4S,5R)-6-((4-chloro-3'-(((2-(2-hydroxycyclopentyl)-l-oxoisoindolin-5- yl)oxy)methyl)-[l,l'-biphenyl]-3-carbonyl)oxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2- carboxylate
[0164] To a solution of allyl (2S,3S,4S,5R)-6-((4-chloro-3'-(((l-oxo-2-(2-((tetrahydro-2H- pyran-2-yl)oxy)cyclopentyl)isoindolin-5-yl)oxy)methyl)-[l,l'-biphenyl]-3-carbonyl)oxy)- 3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylate (64 mg, 0.08 mmol) in ethanol (10 mL) was added PPTS (20 mg, 0.08 mmol). The mixture was stirred at 50 °C for 18 hrs. The reaction mixture was concentrated and then extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with water (30 mL) and brine (30 mL), dried over Na2SO4 and filtered. The filtrate was concentrated and purified by flash column chromatography (silica gel, eluting with 16% DCM / ethanol) to afford allyl (2S,3S,4S,5R)-6- ((4-chl oro-3 '-(((2-(2-hy droxy cyclopentyl)- 1 -oxoisoindolin-5-yl)oxy )methyl)-[l, l'-biphenyl]- 3-carbonyl)oxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylate (40 mg, 70 %) as a colorless oil. HPLC / UV purity: 90%; LC-MS (ESI): 694.2 (M + 1)+.(2S,3S,4S,5R)-6-((4-chloro-3'-(((2-(2-hydroxycyclopentyl)-l-oxoisoindolin-5- yl)oxy)methyl)-[l,l'-biphenyl]-3-carbonyl)oxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2- carboxylic acid (Compound 9)(Compound 9)
[0165] To a solution of allyl (2S,3S,4S,5R)-6-((4-chloro-3'-(((2-(2-hydroxycyclopentyl)-l- oxoisoindolin-5-yl)oxy)methyl)-[l,l'-biphenyl]-3-carbonyl)oxy)-3,4,5-trihydroxytetrahydro- 2H-pyran-2-carboxylate (40 mg, 0.058 mmol) in THF (2 mL) was added Pd(PPh3)4(6 mg,0.0058 mmol) at 0 °C followed by pyrrolidine (4 mg, 0.058 mmol). The mixture was stirred at 0 °C for 30 min. The reaction mixture was concentrated and purified by prep - HPLC to afford (2S,3S,4S,5R)-6-((4-chloro-3'-(((2-(2-hydroxycyclopentyl)-l-oxoisoindolin-5- yl)oxy)methyl)-[l,l'-biphenyl]-3-carbonyl)oxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2- carboxylic acid (5 mg, 13%) as a white solid. HPLC / UV purity: 100%; LC-MS (ESI): 654.2 (M + 1)+. ‘HNMR (400 MHz, CD3OD) 5 8.25 (d, J= 2.4 Hz, 1H), 7.82 (dd, J= 8.4, 2.4 Hz, 1H), 7.76 (s, 1H), 7.68 (d, J= 8.4 Hz, 1H), 7.66 - 7.63 (m, 1H), 7.61 (d, J= 8.4 Hz, 1H), 7.51 (d, J= 4.8 Hz, 2H), 7.22 (d, J= 2.0 Hz,lH), 7.16 (dd, J= 8.4, 2.4 Hz, 1H), 5.79 - 5.77 (m, 1H), 5.27 (s, 2H), 4.49 (s, 2H), 4.39 - 4.33 (m, 1H), 4.30 (q, 1H), 4.02 (d, J= 9.2 Hz, 1H), 3.63 - 3.58 (m, 1H), 3.56 - 3.54 (m, 2H), 2.07 - 2.04 (m, 2H), 1.82 - 1.79 (m, 3H), 1.70 - 1.61 (m, 1H).Example 17: Synthesis of (2S,3S,4S,5R)-6-((4-chloro-3'-(((2-(3-hydroxycyclopentyl)-l- oxoisoindolin-5-yl)oxy)methyl)-[l,l'-biphenyl]-3-carbonyl)oxy)-3,4,5- trihydroxytetrahydro-2H-pyran-2-carboxylic acid (Compound 7)Scheme:2-(cyclopent-3-en-l-yl)-5-methoxyisoindolin-l-one
[0166] To a solution of l-(4-chl oro-3 -fluorophenyl) ethan-l-one (4.2 g, 34.8 mmol, 3.0 equiv) in DMF (40 mL) was added K2CO3 (4.8g, 34.8 mmol, 3.0 equiv). Then, methyl 2- (bromomethyl)-4-methoxybenzoate (3 g, 11.6 mmol, 1.0 equiv) in DMF (15 mL) was added dropwise. The resulting mixture was stirred at room temperature overnight under N2 atmosphere. The reaction mixture was diluted with water (30 mL) and extracted with EtOAc (3 x 30 mL). The combined organic layers were washed with brine (30 mL), dried over anhydrous ISfeSCU and concentrated. The residue was purified by flash chromatography (eluted with PE / EtOAc = 4 / 1) to afford 2-(cyclopent-3-en-l-yl)-5-methoxyisoindolin-l-one as a solid (2.2 g, 83%). LC-MS (ESI): 230.2 (M+H)+. 'H NMR (400 MHz, DMSO) 5 7.57 (d, J = 8.4 Hz, 1H), 7.13 (d, J = 1.6 Hz, 1H), 7.01 (dd, J = 8.4, 2.4 Hz, 1H), 5.82 (s, 2H), 4.92 - 5.14 (m, 1H), 4.25 (s, 2H), 3.82 (s, 3H), 2.65 (dd, J = 15.2, 8.4 Hz, 2H), 2.37 (dd, J = 15.2, 4.1 Hz, 2H).2-(cyclopent-3-en-l-yl)-5-hydroxyisoindolin-l-one
[0167] To a solution of 2-(cyclopent-3-en-l-yl)-5-methoxyisoindolin-l-one (500 mg, 2.18 mmol) in DCM (30 mL) was added BB (6.5 mL, 1 M in DCM, 6.54 mmol) at 0 °C dropwise under N2. The mixture was stirred at 0 °C for 3 hrs. The reaction mixture was quenched with water (30 mL) and then extracted with DCM (3 x 15 mL). The combined organic layers were washed with water (50 mL) and brine (50 mL), dried over ISfeSCU and filtered. The filtrate was concentrated and purified by flash column chromatography (silica gel, eluting with 33% EtOAc / DCM) to afford 2-(cyclopent-3-en-l-yl)-5-hydroxyisoindolin-l- one (300 mg, 64%) as a white solid. HPLC / UV purity: 95%; LC-MS (ESI): 216.1 (M + 1)+.XH NMR (400 MHz, DMSO-tL) 8 10.05 (s, 1H), 7.45 (d, J= 8.4 Hz, 1H), 6.90 (d, J= 1.6 Hz, 1H), 6.83 (dd, J= 8.4, 2.0 Hz, 1H), 5.81 (s, 2H), 5.02 - 4.90 (m, 1H), 4.20 (s, 2H), 2.63 (dd, J= 15.2, 8.4 Hz, 2H), 2.35 (dd, J = 15.2, 4.0 Hz, 2H).Methyl 4-chloro-3'-(((2-(cyclopent-3-en-l-yl)-l-oxoisoindolin-5-yl)oxy)methyl)-[l,l'- biphenyl] -3-carboxylate
[0168] To a solution of methyl 3'-(bromomethyl)-4-chloro-[l,l'-biphenyl]-3-carboxylate (434 mg, 1.28 mmol) in DMF (6 mL) were added 2-(cyclopent-3-en-l-yl)-5-hydroxyisoindolin-l- one (330 mg, 1.53 mmol) and potassium carbonate (354 mg, 2.56 mmol). The mixture was stirred at 80 °C for 18 hrs. The reaction mixture was quenched with water (50 mL), and then extracted with EtOAc (3 x 15 mL). The combined organic layers were washed with water (50 mL) and brine (50 mL), dried over ISfeSCU and filtered. The filtrate was concentrated and purified by flash column chromatography (silica gel, eluting with 33% EtOAc / DCM) to afford methyl 4-chloro-3'-(((2-(cyclopent-3-en-l-yl)-l-oxoisoindolin-5-yl)oxy)methyl)-[l,l'- biphenyl]-3-carboxylate (470 mg, 78%) as a colorless oil. HPLC / UV purity: 95%; LC-MS (ESI): 474.2 (M+H)+.4-chloro-3'-(((2-(3-hydroxycyclopentyl)-l-oxoisoindolin-5-yl)oxy)methyl)-[l,l'- biphenyl]-3-carboxylic acid
[0169] To a solution of methyl 4-chloro-3'-(((2-(cyclopent-3-en-l-yl)-l-oxoisoindolin-5- yl)oxy)methyl)-[l,l'-biphenyl]-3-carboxylate (470 mg, 0.99 mmol) in THF (12 mL) was added BEtrDMS (0.2 mL, 10 M, 1.98 mmol) slowly at 0 °C. The mixture was stirred at room temperature for 3 hrs. Then the mixture was cooled to 0 °C, NaOH aqueous (5 M, 1.2 mL, 5.94 mmol) was added to the mixture followed by addition of H2O2 (199 mg, 5.84 mmol). The reaction mixture was stirred at room temperature for 16 hrs. The reaction mixture was acidified to pH= 3 with HC1 aqueous (IN) and then extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with water (50 mL) and brine (50 mL), dried over Na2SO4 and filtered. The filtrate was concentrated to afford 4-chloro-3'-(((2-(3- hydroxycyclopentyl)-l-oxoisoindolin-5-yl)oxy)methyl)-[l,l'-biphenyl]-3-carboxylic acid (480 mg, 100%) as a colorless oil. HPLC / UV purity: 90%; LC-MS (ESI): 478.2 (M+H)+.Methyl 4-chloro-3'-(((2-(3-hydroxycyclopentyl)-l-oxoisoindolin-5-yl)oxy)methyl)-[l,l'- biphenyl] -3-carboxylate
[0170] To a solution of 4-chloro-3'-(((2-(3-hydroxycyclopentyl)-l-oxoisoindolin-5- yl)oxy)methyl)-[l,l'-biphenyl]-3-carboxylic acid (480 mg, 1.01 mmol) in EtOAc (10 mL) and methanol (10 mL) was added TMS(CH)N2 (1.01 mL, 2 M, 2.02 mmol) drop wise at 0 °C. The mixture was stirred at room temperature for 2 hrs. The reaction mixture was quenched with water (3 mL), and then extracted with EA (3 x 10 mL). The combined organic layers were washed with water (30 mL) and brine (30 mL), dried over ISfeSCU and filtered. The filtrate was concentrated and purified by flash column chromatography (silica gel, eluting with 50% EtOAc / DCM) to afford methyl 4-chl oro-3 '-(((2-(3 -hydroxy cyclopentyl)- 1- oxoisoindolin-5-yl)oxy)methyl)-[l,l'-biphenyl]-3-carboxylate (200 mg, 40%) as a colorless oil. HPLC / UV purity: 95%; LC-MS (ESI): 492.0 (M+H)+.Methyl 4-chloro-3'-(((l-oxo-2-(3-((tetrahydro-2H-pyran-2-yl)oxy)cyclopentyl)isoindolin-5-yl)oxy)methyl)-[l,l'-biphenyl]-3-carboxylate
[0171] To a solution of methyl 4-chloro-3'-(((2-(3-hydroxycyclopentyl)-l-oxoisoindolin-5- yl)oxy)methyl)-[l,l'-biphenyl]-3-carboxylate (200 mg, 0.41 mmol) and TsOH (7 mg, 0.041 mmol) in DCM (8 mL) was added DHP (51 mg, 0.61 mmol). The mixture was stirred at room temperature for 2 hrs. The reaction mixture was extracted with DCM (3 x 5 mL). The combined organic layers were washed with water (20 mL) and brine (20 mL), dried over Na2SO4 and filtered. The filtrate was concentrated and purified by flash column chromatography (silica gel, eluting with 25% EtOAc / DCM) to afford methyl 4-chloro-3'-(((l- oxo-2-(3-((tetrahydro-2H-pyran-2-yl)oxy)cyclopentyl)isoindolin-5-yl)oxy)methyl)-[l,l'- biphenyl]-3-carboxylate (200 mg, 86%) as a colorless oil. HPLC / UV purity: 90%; LC-MS (ESI): 492.2 (M - 84)+.4-chloro-3'-(((l-oxo-2-(3-((tetrahydro-2H-pyran-2-yl)oxy)cyclopentyl)isoindolin-5- yl)oxy)methyl)-[l,l'-biphenyl]-3-carboxylic acid
[0172] To a solution of methyl 4-chloro-3'-(((l-oxo-2-(3-((tetrahydro-2H-pyran-2- yl)oxy)cyclopentyl)isoindolin-5-yl)oxy)methyl)-[l,l'-biphenyl]-3-carboxylate (330 mg, 0.57mmol) in THF (5 mL) and H2O (5 mL) was added LiOH LO (96 mg, 2.28 mmol). The mixture was stirred at room temperature for 16 hrs. The reaction mixture was concentrated and acidified to pH=4 with IN HC1 aqueous solution. Then the mixture was extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with water (30 mL) and brine (30 mL), dried over Na2SO4 and filtered. The filtrate was concentrated to afford 4-chloro-3'- (((l-oxo-2-(3-((tetrahydro-2H-pyran-2-yl)oxy)cyclopentyl)isoindolin-5-yl)oxy)methyl)-[l,l'- biphenyl]-3-carboxylic acid (300 mg, 93%) as a white solid. HPLC / UV purity: 90%; LC-MS (ESI): 478.0 (M - 84)+.Allyl (2S,3S,4S,5R)-6-((4-chloro-3'-(((l-oxo-2-(3-((tetrahydro-2H-pyran-2- yl)oxy)cyclopentyl)isoindolin-5-yl)oxy)methyl)-[l,l'-biphenyl]-3-carbonyl)oxy)-3,4,5- trihydroxytetrahydro-2H-pyran-2-carboxylate
[0173] To a solution of 4-chloro-3'-(((l-oxo-2-(3-((tetrahydro-2H-pyran-2- yl)oxy)cyclopentyl)isoindolin-5-yl)oxy)methyl)-[l,l'-biphenyl]-3-carboxylic acid (250 mg, 0.45 mmol) in CH3CN (25 mL) were added allyl (2S,3 S,4S,5R)-3, 4,5,6- tetrahydroxytetrahydro-2H-pyran-2-carboxylate (126 mg, 0.54 mmol), HATU (205 mg, 0.54 mmol) and NMM (91 mg, 0.90 mmol). The mixture was stirred at room temperature for 3 hrs. The reaction mixture was concentrated and purified by flash column chromatography (silica gel, eluting with 6% DCM / ethanol) to afford allyl (2S,3S,4S,5R)-6-((4-chloro-3'-(((l- oxo-2-(3-((tetrahydro-2H-pyran-2-yl)oxy)cyclopentyl)isoindolin-5-yl)oxy)methyl)-[l,l'- biphenyl]-3-carbonyl)oxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylate (110 mg, 32%) as a white solid. HPLC / UV purity: 90%; LC-MS (ESI):778.2 (M + 1)+.Allyl (2S,3S,4S,5R)-6-((4-chloro-3'-(((2-(3-hydroxycyclopentyl)-l-oxoisoindolin-5- yl)oxy)methyl)-[l,l'-biphenyl]-3-carbonyl)oxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2- carboxylate
[0174] To a solution of allyl (2S,3S,4S,5R)-6-((4-chloro-3'-(((l-oxo-2-(3-((tetrahydro-2H- pyran-2-yl)oxy)cyclopentyl)isoindolin-5-yl)oxy)methyl)-[l,l'-biphenyl]-3-carbonyl)oxy)- 3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylate (90 mg, 0.12 mmol) in ethanol (5 mL) was added PPTS (30 mg, 0.12 mmol). The mixture was stirred at 50 °C for 18 hrs. The reaction mixture was concentrated and then extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with water (30 mL) and brine (30 mL), dried over Na2SO4 and filtered. The filtrate was concentrated and purified by flash column chromatography (silica gel, eluting with 9% DCM / ethanol) to afford allyl (2S,3S,4S,5R)-6- ((4-chloro-3'-(((2-(3-hy droxy cyclopentyl)- 1 -oxoisoindolin-5-yl)oxy )methyl)-[l, l'-biphenyl]- 3-carbonyl)oxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylate (60 mg, 75%) as a colorless oil. HPLC / UV purity: 90%; LC-MS (ESI): 694.2 (M + 1)+.(2S,3S,4S,5R)-6-((4-chloro-3'-(((2-(3-hydroxycyclopentyl)-l-oxoisoindolin-5- yl)oxy)methyl)-[l,l'-biphenyl]-3-carbonyl)oxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2- carboxylic acid (Compound 7)
[0175] To a solution of allyl (2S,3S,4S,5R)-6-((4-chloro-3'-(((2-(3-hydroxycyclopentyl)-l- oxoisoindolin-5-yl)oxy)methyl)-[l,l'-biphenyl]-3-carbonyl)oxy)-3,4,5-trihydroxytetrahydro- 2H-pyran-2-carboxylate (40 mg, 0.06 mmol) in THF (2 mL) was added Pd(PPhs)4 (7 mg, 0.006 mmol) at 0 °C followed by pyrrolidine (4 mg, 0.06 mmol). The mixture was stirred at 0 °C for 30 min. The reaction mixture was concentrated and purified by prep - HPLC to afford (2S,3S,4S,5R)-6-((4-chloro-3'-(((2-(3-hydroxycyclopentyl)-l-oxoisoindolin-5- yl)oxy)methyl)-[l,l'-biphenyl]-3-carbonyl)oxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2- carboxylic acid (6.5 mg, 17%) as a white solid. HPLC / UV purity: 100%; LC-MS (ESI):654.2 (M + 1)+. ‘HNMR (400 MHz, CD3OD) 5 8.24 (d, J= 2.4 Hz, 1H), 7.81 (dd, J= 8.4, 2.4 Hz, 1H), 7.76 (s, 1H), 7.66 (d, J= 8.4 Hz, 1H), 7.64 - 7.63 (m, 1H), 7.60 (d, J= 8.4 Hz, 1H), 7.50 (d, J= 4.8 Hz, 2H), 7.21 (d, J= 2.0 Hz, 1H), 7.15 (dd, J= 8.4, 2.0 Hz, 1H), 5.79 - 5.78 (m, 1H), 5.26 (s, 2H), 4.42 - 4.40 (m, 4H), 4.02 (d, J= 92 Hz, 1H), 3.62 - 3.54 (m, 3H), 2.17 - 2.13 (m, 2H), 1.97 (q, 2H), 1.74 - 1.69 (m, 2H).Example 18: Synthesis of 4-chloro-3'-(((2-(2-hydroxycyclopent-3-en-l-yl)-l- oxoisoindolin-5-yl)oxy)methyl)-[l,l'-biphenyl]-3-carboxylic acid (Compound 13) Scheme:(Compound 13)Methyl 4-chloro-3'-(((2-(2-hydroxycyclopent-3-en-l-yl)-l-oxoisoindolin-5- yl)oxy)methyl)- [1 , 1 '-biphenyl] -3-carboxylate
[0176] To a solution of methyl 4-chloro-3'-(((2-(cyclopent-3-en-l-yl)-l-oxoisoindolin-5- yl)oxy)methyl)-[l,l'-biphenyl]-3-carboxylate (480 mg, 1.01 mmol) in dioxane : pyridine : water (100:10: 1) (8 mL) was added SeCL (224 mg, 2.02 mmol) . The resulting mixture was stirred at 100 °C overnight under N2 atmosphere. The solution was quenched with water (20 mL). The resulting mixture was diluted with water (20 mL) and extracted with EtOAc (3 x 15 mL). The combined organic layers were washed with brine (20 mL), dried over anhydrous Na2SO4 and concentrated. The residue was purified by flash chromatography (eluted with DCMZEtOAc = 1 / 1) to afford methyl 4-chl oro-3 '-(((2-(2-hydroxy cyclopent-3 -en-l-yl)-l- oxoisoindolin-5-yl)oxy)methyl)-[l,l'-biphenyl]-3-carboxylate as a white solid (67 mg, 26% yield,). LC-MS(ESI): 512 (M+Na)+.‘HNMR (400 MHz, DMSO-tL) 8 8.08 (d, J= 2.4 Hz, 1H), 7.90 (dd, J= 8.4, 2.4 Hz, 1H), 7.83 (s, 1H), 7.69 (d, J= 8.4 Hz, 2H), 7.60 (d, J= 8.4 Hz,1H), 7.53 (d, J= 5.2 Hz, 2H), 7.26 (s, 1H), 7.14 (dd, J= 8.4, 2.0 Hz, 1H), 5.88 (d, J= 4.8 Hz, 1H), 5.81 - 5.72 (m, 1H), 5.28 (s, 2H), 5.16 (s, 1H), 4.78 (s, 1H), 4.55 - 4.45 (m, 1H), 4.37 (s, 2H), 3.90 (s, 3H), 2.68 - 2.55 (m, 1H), 2.43 - 2.33 (m, 1H).4-chloro-3'-(((2-(2-hydroxycyclopent-3-en-l-yl)-l-oxoisoindolin-5-yl)oxy)methyl)-[l,l'- biphenyl]-3-carboxylic acid (Compound 13)
[0177] To a solution of methyl 4-chl oro-3 '-(((2-(2 -hydroxy cyclopent-3 -en-l-yl)-l- oxoisoindolin-5-yl)oxy)methyl)-[l,T-biphenyl]-3-carboxylate (130 mg, 0.27 mmol) in THF / H2O (4 mL:4mL) was added LiOH H2O (44.6 mg, 1.06 mmol). The resulting mixture was stirred at room temperature for 3 hours. Then the reaction mixture was adjusted to pH = 5 ~ 6 with HCOOH. The mixture was extracted with EtOAc (3 ' 5 mL). The organic combined layers were washed with water (10 mL) and brine (10 mL), dried over Na2SO4, concentrated and purified with Prep-HPLC to afford 4-chl oro-3 '-(((2-(2-hy droxycy cl opent-3 - en-l-yl)-l-oxoisoindolin-5-yl)oxy)methyl)-[l,l'-biphenyl]-3-carboxylic acid as white solid (28 mg, 22% yield). LC-MS(ESI): 476.2 (M+H)+. *HNMR (400 MHz, CD3OD) 5 8.07 (d, J = 2.4 Hz, 1H), 7.79 - 7.71 (m, 2H), 7.68 (d, J= 8.4 Hz, 1H), 7.64 - 7.59 (m, 1H), 7.57 (d, J= 8.4 Hz, 1H), 7.50 (d, J= 5.2 Hz, 2H), 7.21 (s, 1H), 7.16 (dd, J= 8.4, 2.2 Hz, 1H), 5.98 (dd, J = 4.0, 1.6 Hz, 1H), 5.91 - 5.74 (m, 1H), 5.27 (s, 2H), 4.96 - 4.92 (m, 1H), 4.65 (dt, J= 8.0, 6.4Hz, 1H), 4.44 (s, 2H), 2.85 - 2.42 (m, 2H).II. Pharmaceutical Compositions Example 1: Parenteral Composition
[0178] To prepare a parenteral pharmaceutical composition suitable for administration by injection, 100 mg of a water-soluble salt of a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt or solvate thereof, is dissolved in 2% HPMC, 1% Tween 80 in DI water, pH 2.2 with MSA, q.s. to at least 20 mg / mL. The mixture is incorporated into a dosage unit form suitable for administration by injection.Example 2: Oral Composition
[0179] To prepare a pharmaceutical composition for oral delivery, 100 mg of a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt or solvate thereof, is mixed with 750 mg of starch. The mixture is incorporated into an oral dosage unit, such as a hard gelatin capsule, which is suitable for oral administration.III. Biological Evaluation Example 1: mGlu receptor in vitro assays.
[0180] Human Embryonic Kidney (HEK-293) cell lines co-expressing rat mGlu receptors 2, 3, 4, 6, 7 or 8 and G protein-coupled inwardly-rectifying potassium (GIRK) channels were grown in Growth Media containing 45% DMEM, 45% F-12, 10% FBS, 20 mM HEPES, 2 mM L-glutamine, antibiotic / antimycotic, non-essential amino acids, 700 pg / mL G418, and 0.6 pg / mL puromycin at 37 °C in the presence of 5% CO2. Cells expressing rat mGlul and mGlu5 receptor were cultured as described in Hemstapat et al (Mol. Pharmacol. 2006, 70, 616-626). All cell culture reagents were purchased from Invitrogen Corp. (Carlsbad, CA) unless otherwise noted. Calcium assays were used to assess activity of compounds at mGlul and mGlu5, as previously described in Engers et al (J. Med. Chem. 2009, 52, 4115-4118). Calcium assays at mGlu3 were performed as described for mGlu5 with the exception that TREx293 mGlu3 Gal 5 cells were treated with tetracycline at 20 ng / mL for 20 h prior to assay.
[0181] Compound activity at the group II (mGlu2 and mGlu3) and group III (mGlu4, mGlu6, mGlu7, and mGlu8) was assessed using thallium flux through GIRK channels, a method that has been described in detail. Briefly, cells were plated into 384-well, black-walled, clear- bottomed poly-D-lysine-coated plates at a density of 15,000 cells / 20 pL / well in DMEM containing 10% dialyzed FBS, 20 mM HEPES, and 100 units / mL penicillin / streptomycin (assay media). Plated cells were incubated overnight at 37 °C in the presence of 5% CO2. The following day, the medium was exchanged from the cells to assay buffer [Hanks’ balanced salt solution (Invitrogen) containing 20 mM HEPES, pH 7.3] using an ELX405 microplate washer (BioTek), leaving 20 pL / well, followed by the addition of 20 pL / well FluoZin2-AM (330 nM final concentration) indicator dye (Invitrogen; prepared as a stock in DMSO and mixed in a 1 : 1 ratio with Pluronic acid F-127) in assay buffer. Cells were incubated for 1 h at room temperature, and the dye exchanged to assay buffer using an ELX405, leaving 20 pL / well. Test compounds were diluted to 2 times their final desired concentration in assay buffer (0.3% DMSO final concentration). Agonists were diluted in thallium buffer [125 mM sodium bicarbonate (added fresh the morning of the experiment), 1 mM magnesium sulfate, 1.8 mM calcium sulfate, 5 mM glucose, 12 mM thallium sulfate, and 10 mM HEPES, pH 7.3] at 5 times the final concentration to be assayed. Cell plates and compound plates were loaded onto a kinetic imaging plate reader (FDSS 6000 or 7000; Hamamatsu Corporation, Bridgewater, NJ). Appropriate baseline readings were taken (10 images at 1 Hz; excitation, 470 ± 20 nm; emission, 540 ± 30 nm) and test compounds were added in a 20 pL volume andincubated for approximately 2.5 min before the addition of 10 pL of thallium buffer with or without agonist. After the addition of agonist, data were collected for approximately an additional 2.5 min. Data were analyzed using Excel (Microsoft Corp, Redmond, WA). The slope of the fluorescence increase beginning 5 s after thallium / agonist addition and ending 15 s after thallium / agonist addition was calculated, corrected to vehicle and maximal agonist control slope values, and plotted in using either XLfit (ID Business Solutions Ltd) or Prism software (GraphPad Software, San Diego, CA) to generate concentration-response curves. Potencies were calculated from fits using a four-point parameter logistic equation. For concentration-response curve experiments, compounds were serially diluted 1 :3 into 10-point concentration response curves and were transferred to daughter plates using an Echo acoustic plate reformatter (Labcyte, Sunnyvale, CA). Test compounds were applied and followed by EC20 concentrations of glutamate. For selectivity experiments, full concentration-response curves of glutamate or L-AP4 (for mGlu7) were performed in the presence of a 10 pM concentration of compound and compounds that affected the concentration-response by less than 2-fold in terms of potency or efficacy were designated as inactive.
[0182] Representative in vitro biochemical data for mGlu2 is presented in Table 2.Table 2
[0183] While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood thatvarious alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.
Claims
CLAIMSWhat is claimed is:
1. A compound of F ormula (I) :Formula (I), or a pharmaceutically acceptable salt thereof; wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11are each selected from hydrogen or deuterium, provided that at least one of R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11is deuterium; and wherein each of R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11that is deuterium has a deuterium enrichment of at least 90%.
2. The compound of claim 1, wherein at least one of R10and R11is deuterium.
3. The compound of claim 2, wherein R10and R11are each deuterium.
4. The compound of any one of claims 1 to 3, wherein at least two of R1, R2, R3, R4, R5,R6, R7, R8, and R9are deuterium.
5. The compound of claim 4, wherein at least four of R1, R2, R3, R4, R5, R6, R7, R8, and R9are deuterium.
6. The compound of claim 5, wherein R4, R5, R6, and R7are each deuterium.
7. The compound of claim 5 or claim 6, wherein R2, R3, R8, and R9are each deuterium.
8. The compound of any one of claims 5 to 7, wherein R1, R2, R3, R8, and R9are each deuterium.
9. The compound of claim 1, wherein the compound is selected from:or a pharmaceutically acceptable salt thereof.
10. The compound of any one of claims 1 to 9, wherein each of R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11that is deuterium has a deuterium enrichment of at least about 95%.
11. The compound of claim 10, wherein each of R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11that is deuterium has a deuterium enrichment of at least 98%.
12. The compound of any one of claim 1 to 11, wherein each of R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11that is deuterium has a deuterium enrichment of no more than 99.9%.
13. A pharmaceutical composition comprising a compound of any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
14. A compound of Formula (II):Formula (II), or a pharmaceutically acceptable salt thereof; wherein ring B is selected from (i) cyclopentyl substituted with one or more -OH, (ii) unsubstituted cyclopentyl, or (iii) cyclopentenyl optionally substituted with one or more -OH; and W is hydrogen or a pyranyl substituted by one or more groups independently selected from - OH and -C(=O)OH.
15. The compound of claim 14, or a pharmaceutically acceptable salt thereof, wheren: ring B is unsubstituted cyclopentyl.
16. The compound of claim 14, or a pharmaceutically acceptable salt thereof, wherein: ring B is cyclopentyl substituted with -OH.
17. The compound of claim 16 or a pharmaceutically acceptable salt thereof, wherein: ring B18. The compound of claim 14 or a pharmaceutically acceptable salt thereof, wherein: ring B is cyclopentenyl optionally substituted with one or more -OH.
19. The compound of claim 18 or a pharmaceutically acceptable salt thereof, wherein: ring B20. The compound of any one of claims 14 to 19 or a pharmaceutically acceptable salt thereof, wherein W is selected from: hydrogen21. The compound of any one of claims 14 to 19 or a pharmaceutically acceptable salt thereof, wherein W is hydrogen.
22. The compound of claim 14 or a pharmaceutically acceptable salt thereof, selected from:
23. A pharmaceutical composition comprising a compound of any one of claims 14-22, or a pharmaceutically acceptable salt, or solvate thereof, and at least one pharmaceutically acceptable excipient.
24. The pharmaceutical composition of claim 13 or 23, wherein the pharmaceutical composition is formulated for administration to a mammal by intravenous administration, subcutaneous administration, oral administration, inhalation, nasal administration, dermal administration, or ophthalmic administration.
25. The pharmaceutical composition of claim 24, wherein the pharmaceutical composition is in the form of a tablet, a pill, a capsule, a liquid, a suspension, a gel, a dispersion, a solution, an emulsion, an ointment, or a lotion.
26. A method of treating a central nervous system (CNS) disorder in a subject in need thereof, the method comprising the step of administering to the subject in need thereof, a therapeutically effective amount of the compound of any one of claims 1-23 or a pharmaceutically acceptable salt thereof, thereby treating the disorder.
27. The method of claim 26, wherein the CNS disorder is an addictive disorder.
28. The method of claim 27, wherein the addictive disorder is a nicotine addiction, an alcohol addiction, an opioid addiction, an amphetamine addiction, a methamphetamine addiction, or a cocaine addiction.
29. The method of claim 28, wherein the addictive disorder is a nicotine addiction.
30. The method of claim 28, wherein the addictive disorder is a cocaine addiction.
31. The method of claim 27, wherein the CNS disorder is schizophrenia.
32. The method of claim 27, wherein the CNS disorder is a neurodegenerative disease.
33. The method of claim 32, wherein the neurodegenerative disease is Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, or Lou Gehrig's disease (Amyotrophic Lateral Sclerosis or ALS).
34. A method of treating substance abuse in a subject in need thereof, the method comprising a step of administering to the subject in need thereof, a therapeutically effective amount of the compound of any one of claims 1-22 or a pharmaceutically acceptable salt thereof, wherein the therapeutically effective amount is sufficient to diminish, inhibit or eliminate desire for and / or consumption of the substance in the subject.
35. The method of claim 34, wherein the substance is nicotine, alcohol, an opioid, an amphetamine, a methamphetamine, or cocaine.
36. A method for treating an addictive disorder in a subject in need thereof, the method comprising the steps of: a) administering to the subject an effective amount of a compound of any one of claims 1-23, or a pharmaceutically acceptable salt thereof, during a first time period wherein the subject expects to be in an environment in which the subject habitually uses an addictive substance, or exposed to stimuli which results in the subject habitually using an addictive substance; and b) administering to the subject an effective amount of a compound of any one of claims 1-23, or a pharmaceutically acceptable salt thereof, during a second time period wherein the subject is suffering from withdrawal.
37. The method of claim 36, wherein the addictive disorder is nicotine addiction.
38. The method of claim 36, wherein the addictive disorder is alcohol addiction.
39. The method of claim 36, wherein the addictive disorder is opioid addiction.
40. The method of claim 36, wherein the addictive disorder is amphetamine addiction.
41. The method of claim 36, wherein the addictive disorder is methamphetamine addiction.
42. The method of claim 36, wherein the addictive disorder is cocaine addiction.
Citation Information
Patent Citations
Positive allosteric modulators of group ii mglurs
WO2011116356A2
Cited By
Treatments for pathological repetitive behaviours
WO2026052975A1
